証券取引委員会 （ 「 SEC 」 ） や州証券委員会は、これらの有価証券の承認または不承認、または本目論見書の正確性または妥当性について判断していません。反対の表現は刑事犯罪です。

本募集説明書の日付は

5 月 13 日 カタログ表

目次ページ ページ 説明的説明

II

この目論見書について 三、三、 業界 · 市場データのソース

三、三、

前向き陳述に関する警告説明

四募集説明書の概要 13供物2.69.

リスク要因収益の使用コミット · エクイティ · ファシリティ

クラス A の市場価格普通株と配当

監査を受けていない備考簡明合併財務諸表

商売人管理する, 2024.

証券説明書

一般経済と社会問題

私たちのビジネスや産業に関するリスクは

私たちは初期段階にある会社で、限られた経営歴史は私たちの未来の見通しと私たちが直面する可能性のあるリスクと挑戦を評価することを困難にします。私たちは私たちが収入増加を維持するかどうか予測できない。私たちの業務は運営中に赤字が発生し、私たちの費用が増加することが予想され、近い将来赤字を継続する可能性があります。私たちは運営から十分な収入を得たり、私たち自身を維持することができないかもしれない。私たちが利益を達成したり維持したりすることを保証することはできません。私たちの監査人は、私たちが継続的に経営している企業として経営を続ける能力に大きな疑いを抱いています。

私たちは未来に私たちの商業計画を実行するためにもっと多くの資金を集めなければならない。

私たちは新しい業務、製品、そして技術を獲得したり統合したりすることに成功しないかもしれない。

もし私たちの顧客が彼らの製品を市場の広範な受け入れを得ることができず、彼らの製品に私たちの製品が含まれていれば、私たちの業務を支援するために必要な収入を生むことができないかもしれません。

私たちの顧客は一般的に私たちの製品が長い認証過程を経ることを要求する。

•        我々の5 G半導体製品の市場はまだ発展中であり、予想通りに発展しない可能性がある。

•        もし私たちが私たちの成長戦略を効果的に実行できなければ、私たちの業務は不利な影響を受けるかもしれない。

•        私たちの半導体製品と解決策の市場競争は非常に激しい。

•        私たちの製品と解決策は激しい競争に直面している。

私たちの顧客の統合や垂直統合は私たちの財務業績に悪影響を及ぼすかもしれない。

私たちは普通そんなに時間がありません-1-Term

カタログ表“株式認証協定修正案”によると、私たちに提出されたクレームは最終的かつ拘束力のある仲裁によって解決されなければならず、仲裁は一連の手続きに従っており、訴訟よりも限定的である可能性がある。チャバンテと大陸株式譲渡会社が締結した引受権証協定の改正案は，期日は12月である2023年2月21日(“権証合意修正案”)によると、ニューヨーク州の法律によると、権利証合意修正案またはその実行、違反、終了または有効性に関連する紛争、論争またはクレームは、契約または侵害行為においても、カリフォルニア州オーランド県の中立的かつ公正な仲裁人に提出され、最終的かつ拘束力のある仲裁を行わなければならない。したがって、権利証所有者は連邦または州裁判所で私たちを提訴することができず、逆に、最終的かつ拘束力のある仲裁手続きを通じてこのようなクレームを提起することが要求されるだろう。“授権協定修正案”では、このような仲裁手続きは一般にJAMSによって管理され、JAMS“包括的仲裁ルールとプログラム”に規定されているルールと政策に基づいて行われると規定されている。連邦や州裁判所の訴訟と比較して、このような規則と政策が提供する権利ははるかに限られているかもしれない。株式証合意修正案の強制仲裁条項は、権利証所有者が私たちにクレームを出すのを阻止し、弁護士がこのような当事者を代表して私たちにクレームを出すことに同意することを阻止する可能性がある。任意の権益を購入またはその他の方法で取得または所有する個人またはエンティティは、強制仲裁規定に了承され、同意されたとみなされるべきである。“株式認証協定改正案”の強制仲裁条項は、連邦証券法及びその規則及び条例を遵守する責任を解除しない。株式証合意修正案の条項は連邦と州法律の下で実行可能であり、連邦証券法のクレームに関する条項を含むと考えられるが、その実行可能性には不確実性があり、最終的には実行不可能と決定される可能性がある。デラウェア州の法律と憲章と定款の条項は買収提案をより困難にするかもしれない。憲章、定款、およびデラウェア州法律のいくつかの条項は、株主が有利と思われるかもしれない合併、要約買収、代理競争または他の制御権変更取引を阻止、延期、延期、阻止する可能性があり、私たちA種類の普通株の割増を招く可能性のある試みを含む。他の事項を除いて、憲章と付例は以下の条項を含むBクラス普通株式の保有者が、その大多数が私たちの経営陣であり、株主の承認を必要とする事項を制御することができた結果、Mobix Labsが発行したA類普通株およびB類普通株の多数の株式よりもはるかに少ない株式を所有することができるようにする二層普通株式構造を提供する3つのレベルの取締役会を規定しています-年だ

条項、これは株主が取締役会の多数のメンバーの能力を変更することを延期するかもしれないB類普通株がまだ発行されていない限り、当時発行されていたB類普通株の多数の投票権を持つ所有者は、3人の取締役会メンバー(“B類取締役”)を選出する権利があり、3人のB類取締役がいれば、各カテゴリには1人以下のB類取締役が含まれることが規定されている役員選挙での累積投票を禁止することは、小株主が取締役候補を選挙する能力を制限している取締役会には、取締役会の拡大または1人の取締役がモビックス実験室の種類や一連の株式所有者選挙によって生じた欠員ではないこと、または憲章に基づいて株主が取締役会の空きを埋めることを阻止することが規定されている取締役会が“空白小切手”優先株を含む普通株と優先株を発行することを許可し、株主の承認なしにこれらの株式の価格およびその他の条項を決定することは、敵意の買収者の所有権を著しく希釈するために使用される可能性がある優先株および投票権を含むカタログ表年次または特別株主会議での株主の行動を強要する書面同意による株主行動を禁止するが、B類普通株主のいずれの会議でも、会議や書面の同意なしに行うことができる株主特別会議(A)取締役会議長、最高経営責任者またはモビックス実験室の総裁またはモビックス実験室取締役会のみによって開催されること、および(B)モビックス実験室が発行された株式の10%以上の投票権を有する株主の書面請求(憲章および定款に基づいて提出されなければならない)を要求し、取締役会の開催は、株主が取締役を罷免する能力を含む提案または行動を強制的に考慮することを延期する可能性がある取締役会選出の指名について事前に通知する要件（ 憲章に基づき Mobix Labs の資本株の種類またはシリーズの保有者が選出した取締役を除く。当初はクラス b 取締役 ） または年次株主総会において株主が行動できる事項を提案する（ Mobix Labs のいかなるクラスまたは一連の資本株の保有者が憲章に従って単一のクラスとして投票する権利を有する事項を除く ） 、株主が年次株主総会に問題を提起することを妨げ、取締役会の変更を遅らせる可能性があり、また、潜在的な買収者が買収者を選出するための代理人の勧誘を行うことを妨げるまたは抑止する可能性があります。自身の取締役名簿または会社の支配権を取得しようとすることプリンシパルキャピタル II純利益

株式の売却について

A類普通株

B に。ライリープリンシパル 資本 II Under the 調達協定

$2.00$$3.00

$$3.43$$4.00$$5.00$購入契約では、クラス A 普通株式を b に最大 1 億ドルの売却することが定められていますが、ライリープリンシパルキャピタル II 、我々はちょうど 950 万を登録しています調整、調整3 ヶ月終了

•        十二月三十一日

•        Mobix Labs

•        (歴史)

•        EMI

•        解決策

•        (歴史)

•        形式的には組み合わせている純収入

•        製品販売

•        $

•        $-19$

•        $

•        コストと支出

•        収入コスト研究 · 開発販売、一般、行政

•        4 （ A ）

•        営業収入(赤字)

利子費用取引コスト支出収益負債の公正価値の変更PIPE メイクホール責任の公正価値の変更プライベートワラントの公正価値の変化金庫の公正価値変動所得税前収入

$$$

•        $

•        基本的に1株当たりの純収入$$

•        希釈して普通株当たり純収益

•        $

•        $

•        加重平均は普通株式を発行しています

•        4 （ b ）

•        加重平均は普通株式を発行し、希釈した後

•        4 （ B ）

•        カタログ表

•        監査を受けていない備考簡明合併業務報告書

•        2023 年 9 月 30 日期-19(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

•        現在までの年度

九月三十日現在までの年度六月三十日

ジェームズ · アラリス ：

首席技術官この議論は転送を含む場合があります-そうだな 将来の報酬プログラムに関する当社の現在の計画、考慮事項、期待および決定に基づいた記述。

報酬総額表以下の表は、 2023 年 9 月 30 日および 2022 年 9 月 30 日を末日とする会計年度における任命された執行役員に対する報酬に関する情報を示します。

報酬総額表

名称と主要ポスト

年.年

賃金.賃金($)ボーナス.ボーナス

利点と特典 2023 年 9 月 30 日および 2022 年 9 月 30 日を末日とする会計年度においては、医療、歯科、視覚、生命、 AD & D 、短期および長期を含む全従業員と同じ基準で、任命された執行役員に給付金を支付しました。 -Term

2023 年度優秀株式賞

年末.年末以下の表は、 2023 年 9 月 30 日現在における各執行役員について、出資報酬の発行状況を示します。オプション大賞

名前.名前

賞を授与する

授与日

数量 証券 30, 2024.

潜在的な 体を鍛えていない オプション 練習可能である 数量 証券 潜在的な 体を鍛えていない オプション 行使できない 選択権

価格選択権満期になる 日取りファビアン · バッタリア2020 年 8 月 11 日

$ 2020 年 8 月 11 日 $ 2022 年 5 月 5 日

キーバン · サミニ 2020 年 8 月 11 日 $ 30, 2024.

2020 年 8 月 11 日

2022 年 5 月 5 日

ジェームズ · アラリス2022年5月1日

$

•        2022 年 5 月 15 日

•        

•        $

•        2023 年 4 月 15 日

•        

•        $

•        注 ： 上表の株式数は、 2021 年 2 月 5 日の 1 ： 17 の逆分割により調整されています。

•        このオプションは 205，882 をカバー

•        クラス A 普通株式は、 2020 年主要従業員エクイティ · インセンティブ · プランの下で付与されました。このオプションは 14 の対象となります。

•        -月だ

•         2021 年 1 月 15 日に株式総数の 10% を、その後毎月記念日に株式総数の 10% を譲渡し、各譲渡日までの継続的な業務を条件とします。

•        -タイム誌

•         現在の非自治体に 20，000 RSU の付与-19-従業員

•         取締役

•        12 月以降の次回理事会で 2 万件の RSU の年間授与

•        21 、 2024 年；

•        取締役会の最初の選挙または任命に際し、プロ

•        — 評価

1 年間 2 万の RSU の量ですこれらの RSU は、取締役の継続的な勤務を条件として、 1 年間の期間にわたって毎月付与され、取締役会が決定する時間まで交付されません。また、取締役会は、株主の承認を得て、以下の非株主に対する RSU の付与を承認しました。

ナスダック株式の上場に影響を与えた取締役 ：

ジェームズ · ピーターソン 1，05 万 RSU

フレデリック · ゲーナー 1，050，000 RSU

デイヴィッド · オルドリッチ 50，000 RSU

カート · ブッシュ 50，000 RSU

ウィリアム · カープー 50，000 RSU

カタログ表

証券説明書

ごく普通である

在庫品

% of

電源.電源役員および行政員ファビアン · バッタリアキーバン · サミニジェームズ · アラリスジェームズ · ピーターソンデイヴィッド · オルドリッチ

クルト · ブッシュ

ウィリアム · カープー

フレデリック · ゲーナーマイケルロンググループとしての取締役 · 執行役員全員 （ 個人 9 名 ）5% 以上の保有者江馬Chavant ファミリーオフィス LLCSage Hill Investors ， LLC

売却株主名

数量

•        の株

•        クラス A 共通

•        株益益

•        前に持っていたのは

•        提供するまで

本目論見書に基づき発行するクラス A 普通株式の最大数

数量

の株

利益を得た株

オーナー後

奉納する

番号をつける

パーセント

番号をつける

•        パーセント

•        B 。Riley Principal Capital II ， LLC

•        ルール 13 d に従って

•        Mobix Labs， Inc.）監査済み財務諸表 （ 2023 年 9 月 30 日および 2022 年 ）

•        独立公認会計士事務所報告

•        F — 2

•        2023 年 9 月 30 日および 2022 年 9 月 30 日現在のバランスシート

•        F—3

•        2023 年 9 月 30 日期および 2022 年 9 月 30 日期における営業および包括損失計算書

•        F — 4

2023 年 9 月 30 日期および 2022 年 9 月 30 日期における償還可能優先株式および株主赤字計算書F — 52023 年 9 月 30 日期および 2022 年 9 月 30 日期キャッシュ · フロー計算書

財務諸表付記

F—7

Mobix Labs， Inc.未監査連結財務諸表 （ 2023 年 12 月 31 日期および 2022 年 12 月期 ）2023 年 12 月 31 日および 2023 年 9 月 30 日現在の貸借対照表 （ 未監査 ）F — 362023 年 12 月期および 2022 年 12 月期 3 ヶ月間の営業決算および総合損益計算書 （ 未監査 ）F—38

2023 年 12 月 31 日期および 2022 年 12 月 31 日期における償還可能優先株式および株主自有権 （ 赤字 ） 計算書 （ 未監査 ）F—392023 年 12 月期および 2022 年 12 月期 3 ヶ月間のキャッシュ · フロー計算書 （ 未監査 ）

F—40

財務諸表付記(監査なし)

F—42

EMI Solutions， Inc.監査済み財務諸表 2023 年 6 月 30 日および 2022 年

独立監査人報告書

バランスシート 2023 年 6 月 30 日および 2022 年 6 月 30 日F—702023 年 6 月 30 日期および 2022 年 6 月 30 日期における営業決算表F—712023 年 6 月 30 日および 2022 年 6 月 30 日期における株主資本計算書

F — 722023 年 6 月 30 日期および 2022 年 6 月 30 日期キャッシュ · フロー計算書F — 73

財務諸表付記

F—74

EMI ソリューションズ株式会社2023 年 9 月 30 日期および 2022 年 9 月 30 日期 3 ヶ月間の監査済み財務諸表2023 年 9 月 30 日および 2022 年 9 月 30 日現在のバランスシート （ 未監査 ）F — 83

/s/普華永道会計士事務所

•        カリフォルニア州オーウェン-192023 年 12 月 28 日 （ 財務諸表注釈 1 に記載されている逆資本増強の影響を除き、 4 月 ）

•        2022年以来、私たちは会社の監査役を務めてきた。F — 2カタログ表

•        MOBIX LABS OPERATIONS 株式会社

•        （ 旧 Mobix Labs ， Inc. ）

貸借対照表

9月30日まで

資産流動資産-2現金-19$-19$

売掛金純額普通株式発行債権在庫品

前払い費用と他の流動資産

流動資産総額

財産と設備、純額

無形資産、純額

グッドウィル/経営的リース使用権資産

繰延取引コスト

総資産$$

債務、償還可能転換優先株式

株主赤字について

経常負債

売掛金

•        $

•        $

費用とその他の流動負債を計算しなければならない

•        不測の事態支払手形有償債券 — 関連当事者

•        未来株式の単純契約 （ SAFE ） について賃貸負債を経営し、流動流動負債総額

•        非流通両替手形

非流動経営賃貸負債負債総額引受金及び又は事項(付記12)転換可能優先株を償還する創業者可転換優先株式、 $0.00001 額面、 60 万株認可、 2023 年 9 月 30 日および 2022 年 9 月 30 日時点で発行済および発行済 58 8，235 株シリーズ A 転換優先株、 0.00001 ドルの額面価値、 2，000，000 株の認可、 2023 年 9 月 30 日および 2022 年 9 月 30 日時点で発行済および発行済 1，66 6，666 株、 2023 年 9 月 30 日および 2022 年 9 月 30 日時点で清算優先株 2，300 ドル株主損失額

•        普通株式、 0.00001 ドルの額面価値、 57，400，000 株の認可、 2023 年 9 月 30 日時点で 16，69 2，175 株、 2022 年 9 月 30 日時点で 11，86 8，397 株の発行済株式。

追加実収資本

赤字を累計する株主総損失額総負債、償還可能な転換可能優先株、株主損失$$

財務諸表の付記を参照。

F—3

MOBIX LABS OPERATIONS 株式会社

（ 旧 Mobix Labs ， Inc. ）営業 · 損失計算書(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)9 月 30 日終了。純収入

製品販売

$

$許可証収入純収入合計コストと支出収入コスト

研究 · 開発

販売、一般、行政

運営損失

利子費用

所得税前損失

所得税を支給する

純損失と総合損失

$

$普通株1株当たりの基本損失と償却後の純損失$

$加重平均発行済み普通株式、基本普通株式、希釈後普通株財務諸表の付記を参照。F — 4カタログ表MOBIX LABS OPERATIONS 株式会社（ 旧 Mobix Labs ， Inc. ）

交換可能転換優先株式の明細書

株主赤字について

(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

創業者

償還可能である

オープンカー

シリーズA

償還可能である

オープンカー

優先株普通株余分な実収

資本

積算

赤字.赤字

合計する

株主の

赤字.赤字

金額

•        株価

•        金額

•        株価

•        金額

•        2021年9月30日の残高

•        $

•        $

•        $

•        $

•        $

•        $

•        事業取得のために発行された普通株式

•        普通株発行

•        手形を普通株に転換する

•        株式オプションの行使

•        ワラントの行使による普通株式の発行

株に基づく報酬

純損失

2022年9月30日の残高

$

$

$

$$普通株発行

ワラントの行使による普通株式の発行不測の損害賠償のための普通株式の発行サービス提供者への普通株式の発行

社債の普通株式への転換

SAFE を普通株式に転換サービス提供者に対する令状の発行支払手形に関する令状の発行株に基づく報酬

純損失

2023年9月30日の残高

$

$

$

$

$

財務諸表の付記を参照。

F — 5

カタログ表

MOBIX LABS OPERATIONS 株式会社（ 旧 Mobix Labs， Inc. ）現金フロー表(単位：千)9 月 30 日終了。

事業活動

純損失

$純損失と経営活動で使用される現金純額の調整：減価償却無形資産の償却財産と設備処分損失

利子費用を計上する債券に係る令状の発行

金庫の公正価値変動所得税を繰延する他の非現金プロジェクト株に基づく報酬営業資産 · 負債の変動売掛金在庫品

前払い費用と他の流動資産

その他の資産売掛金費用とその他の流動負債を計算しなければならない経営活動のための現金純額投資活動財産と設備を購入する財産と設備を売却して得た収益

投資活動提供の現金純額

資金調達活動

普通株式を発行して得た金

普通株状の行使による収益

支払手形発行による収益 債券発行による収益 — 関連者-8転換手形を発行して得た金SAFE の発行収益債券の元本支払い債券の本金支払 — 関連当事者合併関連の取引費用

融資活動が提供する現金純額 現金の純減少

期初の現金期末現金$ $ キャッシュフロー情報を補充する利子を支払う現金$$所得税の現金を納める非現金投資と融資活動：合併関連の繰延取引コスト$$社債の普通株式への転換SAFE を普通株式に転換

債務割引として計上する買掛債券に係る令状の発行 サービス提供者に対する普通株式およびワラントの発行株式の評価-ベース

報酬と公平性-ベース 賞品

普通株式の評価 善意と長期の損なわれ -生きている

資産

カタログ表

MOBIX LABS OPERATIONS 株式会社 （ 旧 Mobix Labs ， Inc. ） 財務諸表付記

(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

注記 2— 重要な会計方針の概要

（ 続きを読む ）将来の株式のための単純契約の公正価値；事業合併により取得した純資産の購入価格配分および評価

所得税および関連する評価手当および税務不確実性の規定

•        カタログ表

•        MOBIX LABS OPERATIONS 株式会社

•        （ 旧 Mobix Labs ， Inc. ）

•         （“Black— Scholes ”） オプション

•        — 価格設定

モデル。各ストックオプション賞の公正価値は、直線上の補償費用として認識されます。

-回線だ

通常は 4 年間の必要なサービス期間を基準としています当社は没収の説明を選択しました

F—12

カタログ表MOBIX LABS OPERATIONS 株式会社（ 旧 Mobix Labs ， Inc. ）財務諸表付記

•        (単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

•        注記 2— 重要な会計方針の概要

•         （ 続きを読む ）

•        当初はストック記録を記録し

•         すべてのオプション保有者が必要なサービス期間を完了すると仮定する補償費用。従業員が義務勤務期間を満了しなかったため、報酬を喪失した場合、当社は以前に認識された株式を逆転します。

-ベース

賞が没収される期間中の補償費用。

ザ · ブラック-スコアーズ モデルは株式の公正価値を推定する際にいくつかの変数と仮定を考慮しています-ベース 賞だこれらの変数は ：基礎となる普通株式の 1 株当たり公正価値行権価格リスクは-無料だ

金利；期待される期日予想される期間における株価の変動と

予想される年間配当利回り。

期待期間は、株式が

賞は顕著であり続けると予想され、同様の賞の歴史的経験、授与スケジュール、将来の従業員行動の期待に基づいて推定されます。リスク

-無料だ

金利は米国財務省ゼロの利回りに基づいています。

クーポン 株式の予定期間と同等の期間の発行-ベース

2021年10月、会社は顧客とライセンス契約を締結し、その中で会社は顧客に永久、非を授与する

-独占だ その特定の特許と開発された技術の使用を許可する。ライセンスの対価格として、顧客は会社に450ドルの許可料を支払った。ライセンス契約によると、会社は持続的な開発、支援、またはその他の履行義務を負いません。そこで，当社はライセンス契約により履行された義務が履行され，450ドルの対価格を2022年9月30日までの年度の許可収入と確認したと結論した。 F—14カタログ表MOBIX LABS OPERATIONS 株式会社（ 旧 Mobix Labs ， Inc. ）財務諸表付記(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)注記 2— 重要な会計方針の概要 （ 続きを読む ） 収入コスト収入コストには、材料コスト、契約製造サービスコストが含まれ、製品組み立て、テスト、包装および輸送に関連するコスト、入国運賃、開発された技術の償却、在庫廃棄費用、およびその他の製品を含む-関連して コストです。収入コストには従業員の報酬や福祉(株を含む)も含まれている -ベース製品·施設調達に従事する従業員-関連して費用、減価償却、会社コストの分配。広告費 18, 2024.

所得税 （ トピック 740 ） ： 所得税の開示の改善 「 ASU 2023 」

”). ASU 2023 年

財務状況や事業結果に大きな影響を与える可能性があります

注 3— 在庫

在庫には以下の内容が含まれている-3九月三十日

原料

$

$

完成品総在庫.

$

F—16

カタログ表

•        MOBIX LABS OPERATIONS 株式会社

•        （ 旧 Mobix Labs ， Inc. ）

財務諸表付記

•        1,000,000 (単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

•        注 4 — 財産設備、ネット

財産と設備、純額は以下の各項目からなる

使用寿命を見込む

•        (年)

•        九月三十日

•        設備と家具

積算

償却ネットワークがあります発達した技術

$

$

$

$

•        $

•        2023 年 9 月 30 日および 2022 年 9 月 30 日を末日とする会計年度における親善の残高は変更がなかった。

•        注釈 7— 経費およびその他の経常負債

•        計算すべき費用および他の流動負債には以下の項目が含まれる

•        報酬と福祉に計上すべきである

•        $

•        $

•        賃料を繰延する専門費用を計算する応算利息繰延収入他にも

•        費用とその他の流動負債総額を計算しなければならない

•        $

•        $

•        注 8 — 一株当たり純損失

•        当社が純損失を計上している期間については、希釈された 1 株当たり純損失は、すべての希釈可能な有価証券が反逆であるため、 1 株当たり基本純損失と同じです。

•        -希釈剤

•        .以下の表は、当会社の普通株式当たり純損失 （ 基本および希釈 ） の計算を示しています。9 月 30 日終了。分子：

$

$

•        分母：加重平均普通株式残高 （ ベーシックおよび希釈 ）普通株式当たり純損失 （ 基本および希釈 ）

•        $

•        $

•        以下の表は、当会社の普通株式当り純損失の算出に含まれない潜在希釈化有価証券を示しています。9 月 30 日終了。制限株式単位

•        株式オプション

転換優先株式 （ 転換時ベース ）

普通株式引受証

•        転換可能な手形

•        F—18

•        カタログ表

•        MOBIX LABS OPERATIONS 株式会社

•        （ 旧 Mobix Labs ， Inc. ）財務諸表付記(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)

•        注記 9— 負債

債務は以下の部分から構成される

支払手形

$$7% 約束手形 — 関連当事者

有償債券 — 関連当事者

セイフティボックス

転換可能な手形

債務総額

減 ： 現在の金額非流動部分$

$

支払手形

2023 年 9 月 30 日末期に、当社は、運転資本ニーズを満たすために、無関係投資家との間で、総元本額 2，156 ドルの 8 つの支払手形を締結しました。4 枚の手形には年率 6.0% から 8.0% の利子が付与され、残りの手形には無利子が付与されます。2023 年 1 月から 2024 年 3 月の様々な満期日である債券は、無担保であり、満期前の元本支払は必要ありません。当社は、各社債の発行に伴い、合計 239，464 円の買い手令状を発行しました。財務諸表付記

注 11— リース

（ 続きを読む ） 以下の表は、 2023 年 9 月 30 日時点のバランスシートに計上された営業リース負債との割引なしキャッシュ · フローの調整です。 9 月 30 日までの年。 $最低賃貸支払総額差し引く：推定利息将来の最低レンタル支払いの現在価値減算：賃貸項目の下の流動債務

長期賃貸義務 $比較期間の補足情報2022 年 9 月 30 日に終了した年間のリース費用は 565 ドルでした。2022 年 9 月 30 日現在 （ ASC 842 の採択前 ） 非運用リースにおける最低リース支払額—cancelable 1 年を超える期間は以下の通りです。 9 月 30 日までの年。 $

総額 同社の税引前収益の実質的な全てが米国で発生しています。所得税の規定は、以下のとおりです。

9 月 30 日終了。 現在の

$ $

状態.状態

総電流

____________

(1)      九月三十日 繰延税金資産： 純営業損失

(2)      $24,609,287 $第 174 節資本コスト株に基づく報酬

(3)      研究開発単位

利子制限

負債を計算すべきである

他にも

繰延税項目の総資産総額 推定免税額

繰延税金資産 繰延税金負債： 無形資産の償却 固定資産償却 リースROU資産を経営する

他にも

繰延税金負債総額

2023 年 9 月 30 日現在における当社の償還可能優先株式の発行済株式数および関連する換算価格および清算優先株式は以下のとおりです。

株

授権株価発表されました-10786卓越した

発行する．

価格

1株当たり
転換する

価格

職場.職場
加重平均

贈与日交易会

補償費は以下の通り。
9 月 30 日終了。

収益コスト

$ $ 研究 · 開発

販売、一般、行政

株式に基づく報酬総支出

$

$

注 16— 濃度

信用リスクが集中する

当社は、現金を米国内の主要金融機関との口座に、一般的に需要預金の形で保持しています。これらの機関への預金は連邦保険限度を超えることがあります。当社は、信用質の高い金融機関に現金を預け、現金預金の損失は発生していません。

重要な取引先

2023 年 9 月 30 日期には、 2 社のお客様が当社の売上高の 93% を占めました。2022 年 9 月 30 日に終了した年度の売上高の 86% を 2 つの顧客が占めました。2023 年 9 月 30 日現在、 2 社のお客様の未払金残高は、当社売掛金総額の 97% を占めています。2022 年 9 月 30 日現在、 2 社のお客様の未払金残高は、当社の売掛金総額の 76% を占めています。

F—32

カタログ表

MOBIX LABS OPERATIONS 株式会社

（ 旧 Mobix Labs ， Inc. ）     財務諸表付記

注釈 17— 地理情報      地域別収益 船舶による地域別売上高

-行くぞ

製品販売の場所またはライセンス収益の請求先住所は次のように要約されます。     9 月 30 日終了。

アメリカです     $ $

チェコ共和国

タイ

純収入合計
$

$長生きする 資産実質的に、会社の長い-生きている 資産は米国にあります。注 18 — その後の出来事当社は、その後の事象を、財務諸表の発行可能となった 2023 年 12 月 28 日までの評価を行いました。普通株式 · ワラントの発行2023 年 9 月 30 日以降、当社は 480，271 台を販売しました。純利益 3，285 ドルで様々な日付で普通株式をプライベート · プレイスメントしました。これに関連して、当社は 1 人の投資家に対して総額 27，413 円の購入令状を発行しました。-何てこった 関連する契約で定義された期間は $10.0 0 未満です。F—34カタログ表MOBIX LABS OPERATIONS 株式会社（ 旧 Mobix Labs ， Inc. ）財務諸表付記(単位は千で、1株当たりおよび1株当たりの金額は含まれていない)注 18 — その後の出来事

（ 続きを読む ）

また、非法人による— 償還 2023 年 12 月 20 日付の契約により、株主は Chavant と 73，706 株の Chavant 普通株式の償還の選挙を取り下げることに合意しました。非を考慮すると— 償還 Mobix Labs は、 Mobix Labs の普通株式 1 株当たり 0.00001 ドルの購入に対して、株主に対して 202，672 枚のワラントを発行し、そのワラントは 202，489 枚のワラントに転換されました。

合併完了時のクラス A 普通株式の株式。

クローリング時に支払われた対価に加えて、 Mobix Labs の特定の株主および Mobix Labs の特定の保有者は— ザ-金だ Mobix Labs でない既得オプションと Mobix Labs のオプション— ザ

-金だ 付与オプション （ 「収益受領者」 ） は、合計 3，500，000 を追加的に受け取ることができます。取引終了後の取引価格目標の達成に基づき、事業合併契約の条件に従って、収益株式として発行可能なクラス A 普通株式 （ 「収益株式」 ） 。Earnout 株式は 7 つあります。-年だ 閉店 1 年目の日から「稼働期間」 （ 営業期間 ） 。その際は、 1，750，000 円までクラス A 普通株式の VWAP が、連続 30 取引日の間において 20 取引日にわたって 12.50 ドルを超えた場合、さらに 1，750，000 ドルを超えた場合、クラス A 普通株式の株式は、収益受取者に配分されます。クラス A 普通株式の VWAP が、連続 30 取引日の間において 20 取引日にわたって $15.0 0 を超えた場合、クラス A 普通株式の株式は、アークナウト受取者に分配されます。

カタログ表

MOBIX LABS， INC.

簡明合併貸借対照表

（ 未監査、千単位、株式および 1 株当たり金額を除く ）

2023年12月31日

2023年9月30日

資産

流動資産 現金

$

$売掛金純額在庫品

流動資産総額

財産と設備、純額

無形資産、純額

グッドウィル-19経営的リース使用権資産-19繰延取引コスト-19その他の資産

総資産-19$-19$債務、償還可能転換優先株式株主の権益と

経常負債-19売掛金

$

費用とその他の流動負債を計算しなければならない

____________

$

$

簡明な連結財務諸表の付記を参照。

F—37

カタログ表

MOBIX LABS， INC.

業務報告書を簡明に合併する総合収益(損失)と（ 未監査、千単位、株式および 1 株当たり金額を除く ）3 ヶ月一段落した

純収入

製品販売

$$コストと支出

収入コスト

研究 · 開発

販売、一般、行政運営損失利子費用

オーバーフロー負債公正価値変動PIPE メイクホール責任の公正価値の変更プライベートワラントの公正価値の変化金庫の公正価値変動合併関連取引コストの支出所得税前損失所得税を支給する

純収益と総合収益

$$普通株式当り純利益 （ 損失 ） ：

基本的な情報

$$薄めにする

$ $加重平均発行された普通株式：基本的な情報薄めにする簡明な連結財務諸表の付記を参照。F—38カタログ表MOBIX LABS， INC.償還可能な連結明細書

（ 未監査、千単位、株式および 1 株当たり金額を除く ）創始者償還可能であるオープンカー優先株シリーズA償還可能であるオープンカー優先株

偶発的に償還可能である普通株遺贈する普通株

A類普通株クラスB

普通株 その他の内容支払い済み資本積算 赤字合計する株主の株式会社(赤字)株価金額

株価金額株価金額株価金額株価金額株価

金額2023年9月30日の残高$

$

$

$$$$$$

普通株発行

株式会社 EMI ソリューションズの買収に伴う偶発償還普通株式の発行

n c

普通株

支払手形に関する令状の発行

株に基づく報酬

逆資本増強取引純 （ 注釈 3 ）

$

$

普通株発行共通 st の発行パックアップ

株に基づく報酬

純損失

12 月 31 日の残高

$$$

$

$$$$$

簡明な連結財務諸表の付記を参照。

F—39

カタログ表

MOBIX LABS， INC.

簡明合併現金フロー表

(監査を受けておらず、千の計で) 3 か月終了

事業活動

純収益(赤字)$$純収益(損失)と業務活動で使用される現金純額を調整する：減価償却無形資産の償却利子費用を計上する債券に係る令状の発行オーバーフロー負債公正価値変動PIPE メイクホール責任の公正価値の変更

プライベートワラントの公正価値の変化金庫の公正価値変動合併関連取引コストの支出

株に基づく報酬

所得税を繰延する

債券の元本支払い

債券の本金支払 — 関連当事者合併と PIPE による収益合併関連の取引費用融資活動が提供する現金純額現金純増期初の現金期末現金$$F—40カタログ表

MOBIX LABS， INC.連結キャッシュフロー決算書 — （ 続き ）(監査を受けておらず、千の計で)3 か月終了 十二月三十一日キャッシュフロー情報を補充する利子を支払う現金

$

$

所得税の現金を納める

商品の相対公正価値に基づいて、資本に関連する費用 $2，354 を記録しました

-分類 追加支払いの削減としての商品-入力

残りの 4，009 ドルの負債に関連する費用を請求しました-分類 道具を費やす。また、 Chavant の未払い取引コストの負債総額 3，090 ドルも認識し、これは合併時の収益の減少として計上されました。

F—50

スポンサー令状の決済

償還不能株主に対する令状の決済事業合併マーケティング契約の改正合併直前のトータル · チャヴァント株式発行済レガシー Mobix ロールオーバー株式レガシー Mobix 可換紙幣の変換

レガシー Mobix SAFE の変換合併において発行されたクラス A 普通株式の総数クローズ収益 ：チャヴァント信託基金の収益$

PIPE 投資収益

クローズディング支出 ：

Legacy Mobix 合併関連の取引コスト

Chavant 合併関連取引コスト

合併による純現金収益

Mobix 合併関連取引費用のクローズ前に支払ったもの

非現金活動：

Legacy Mobix 可換社債のクラス A 普通株式への転換

レガシー Mobix SAFE のクラス A 普通株式への転換

レガシーモビックス可換優先株式のクラス b 普通株式への転換

未払い合併関連取引費用 Chavant から想定

未払い Legacy Mobix の合併関連取引コスト

合併関連取引コストの支出

負債分類商品 ：

利益負債の公正価値PIPE メイクホール責任の公正価値プライベートワラントの公正価値合併の純出資影響$F — 51カタログ表MOBIX LABS， INC.簡明合併財務諸表付記

注記 4— 証券公共と個人持分証明書 金利は 4.5% 、契約期間は 2 年。当社は、この金額を購入対価額の一部として含めました。2023 年 12 月 21 日に Chavant との合併が完了した後、普通株式は偶発償還可能ではなくなり、当社は偶発償還可能普通株式の価額を 8，856 ドルで恒久資本に再分類し、損益を計上しました。

以下の表は、購入対価の合計額と、取得された有形および特定可能な無形資産およびその推定公正価値に基づいて想定された負債に対する暫定配分額をまとめており、無形資産の評価が確定しています。購入の考慮事項 ：売り手への偶発償還可能普通株式発行$現金対価 （ 現在価額 ）$配分 ：

現金$売掛金在庫品その他流動資産財産と設備その他の資産

無形資産 — 顧客関係無形資産 — バックログ無形資産 — 商品名

使用寿命を見込む(年)十二月三十一日

九月三十日設備と家具$$実験室装置賃借権改善耐用年数や残存賃貸期間が短いと予想されます

建設中の工事財産と設備、毛額減算：減価償却累計財産と設備、純額$$2023 年 12 月 31 日に終了した 3 ヶ月間の減価償却費は、それぞれ 113 ドルと 2023 ドルでした。

毛収入

積算償却ネットワークがあります発達した技術$$$

$$$取引先関係商号

$$

$$$$当社は、 2023 年 12 月 31 日に終了した 3 ヶ月間に、無形資産に関連する償却費用をそれぞれ 237 ドルと 211 ドル計上しました。ウェイト-平均して 2023 年 12 月 31 日時点の無形資産の残存寿命は、開発技術 6.1 年、顧客関係 14.7 年、商品名 2.0 年、バックログ 1.0 年です。

2023 年 12 月 31 日現在の会計年度別無形資産の償却費用の見積もりは以下のとおりです。9 月 30 日までの年。2024 年 （ 残り 9 ヶ月 ）$その後総額$F — 55カタログ表MOBIX LABS， INC.簡明合併財務諸表付記（ 未監査、千単位、株式および 1 株当たり金額を除く ）

•        注 9 — 善意

•        以下の表は、 2023 年 12 月 31 日までの 3 ヶ月間におけるグッドウェルの残高の推移をまとめたものです。2022 年 12 月 31 日までの 3 ヶ月間、親善の計上額に変更はなかった。

•        2023年9月30日の残高$EMI の買収

•        2023年12月31日の残高

•        $

•        注記 10— 経費およびその他の経常負債

計算すべき費用および他の流動負債には以下の項目が含まれる十二月三十一日九月三十日報酬と福祉に計上すべきである$$令状の発行に対する責任

専門費用を計算する応算利息繰延収入未払いの合併関連取引コスト他にも費用とその他の流動負債総額を計算しなければならない$$注 11 — 負債債務は以下の部分から構成される十二月三十一日

九月三十日支払手形MOBIX LABS， INC.簡明合併財務諸表付記（ 未監査、千単位、株式および 1 株当たり金額を除く ）注 11 — 負債(続)

当社は投資家に引受権証を発行し、Legacy Mobix普通株を1株0.01ドルで約4，000株購入した。株式承認証は直ちに行使することができ，かつ1つある-年だ学期です。合併に関連して、発行されたすべての転換可能な手形は会社A類普通株の30，045株に変換され、手形の帳簿価値は206ドルであり、その利息は持分に記入され、収益や損失は確認されない。2023年12月31日現在、未返済の転換可能な手形はありません。注記 12— 公正価値測定不足のため，会社の現金，売掛金，売掛金の帳簿価値はその公正価値に近い-Termこれらの楽器の性質。当社は，債務の帳票価値の合計は，支払手形，7%の引受票と関連側，支払手形と関連側および変換可能手形がそれぞれの貸借対照表日から1年以内に満期または変換されるため，2023年12月31日および2023年9月30日の公正価値に近いと考えている.公正価値階層構造2023年12月31日現在、公正価値に応じて恒常的に計量された負債は以下のとおりである

レベル一

レベル 2

レベル 3総額割増負債

$

$

$

PIPE メイクホール責任私的令状その他の令状総額

$$

$$当社は収益負債を分類し、 PIPE を作る-全体だ レベル 3 金融商品としての債務、プライベート · ワラントその他のワラント、 SAFE は、使用された仮定と公正価値測定に対するこれらの仮定の重要性を策定するために必要な判断によるものです。2023 年 12 月 31 日または 2022 年 12 月 31 日までの 3 ヶ月間、公正価値階層のレベル間で金融商品の移転は行われませんでした。次の表は、レベル 3 の入力を使用して、公正価値で測定された金融商品の残高を繰り返し調整しています。割増価格責任パイプの全体化責任私株式承認証

他にも株式承認証セイフティボックス2023 年 12 月 31 日までの 3 ヶ月間 ：バランス、 2023 年 9 月 30 日$$$$

認識された債務合併におけるクラス A 普通株式への転換純利益 （ 損失 ） に含まれる公正価値の変動

バランス、2023年12月31日

$

$$$

2022 年 12 月 31 日までの 3 ヶ月間 ：

バランス、 2022 年 9 月 30 日$SAFE の発行

純利益 （ 損失 ） に含まれる公正価値の変動

バランス、2022年12月31日$F—58カタログ表MOBIX LABS， INC.簡明合併財務諸表付記（ 未監査、千単位、株式および 1 株当たり金額を除く ）

注記 12— 公正価値測定

(続)

•        割増負債

•        当社は、収益の公正価値を推定します。

-出力

•         ボラティリティ、予想期間、リスクなどの重要な仮定を利用したモンテカルロシミュレーションモデルを使用した負債-無料だ 収益条件を達成する確率を決定するレート。以下の表は、各日付における利益負債の公正価値の推定に使用された仮定をまとめたものです。

•        12 月 21 日、（ 閉館 ）十二月三十一日

•        $

$予想ボラティリティ無リスク金利契約条項8年だ8年だPIPE

•        美化-全体

責任

当社は、ボラティリティ、予想期間、リスクなどの重要な仮定を利用したモンテカルロシミュレーションモデルを使用しています。

-無料だ

PIPE の公正価値を見積もるためにレート-全体だ 責任。以下の表は、 PIPE メイクの公正価値の推定に使用された仮定をまとめたものです。-全体だ 各日付の責任 ：

12 月 21 日、

（ 閉館 ）

十二月三十一日

株価.株価$$

無リスク金利

契約条項

4 カ月4 カ月注 13 — リース当社は、オフィススペースの運営リースを締結しました。リースの残存期間は 6 ヶ月から 3.7 年の範囲で、 2027 年 8 月までの様々な日付で満了します。リースには残留価値保証や制限契約は含まれません。カリフォルニア州アーバインにある 19，436 平方フィートの本社をカバーするリース契約は、当社にさらに 5 年間リースを延長するオプションを提供します。-年だ

当時の市場レートで賃料を支払っていますリースには 400 ドルの保証金が必要であり、これは連結バランスシートの他の資産に計上されます。以下のリース費用は、連結営業利益計算書に含まれます。3 か月終了十二月三十一日リースコストを経営する$

$短期賃貸コスト総賃貸コスト$$2023 年 12 月 31 日に終了した 3 ヶ月間の営業リース負債の計量に含まれる金額に対する現金の支払額は、それぞれ 136 ドルと 132 ドルでした。2023 年 12 月 31 日現在、加重された-平均して

残りリース期間は 3.6 年であり、加重は -平均して

割引率は 15.6% 。当社はいかなる権利も取得しなかった。

-使用する 2023 年 12 月 31 日に終了した 3 ヶ月間の新規営業またはファイナンスリース負債と引き換えに資産2023 年 12 月 31 日時点で未開始のリースは、当社に重要な追加的権利および義務を創設するものではありません。F — 59

カタログ表

MOBIX LABS， INC.    簡明合併財務諸表付記

（ 未監査、千単位、株式および 1 株当たり金額を除く ）注 13 — リース(続)

以下の表は、 2023 年 12 月 31 日時点の連結バランスシートに計上された営業リース負債との割引なしキャッシュ · フローの調整です。9 月 30 日までの年。2024 年 （ 残り 9 ヶ月 ）閉店時には、業績条件を満たし、賞の授与はサービス条件のみの対象となります。その結果、当社は、必要なサービス期間におけるこれらの賞の価値を認識することが求められます。2023 年 12 月 31 日までの 3 ヶ月間において、当社は株式を認識しました。-ベース これらの RSU とワラントに関連する 10，858 ドルの補償費用 （ 漁獲を含む ）-上だ 性能条件が満たされる前に終了したサービス期間の部分について。2023 年 12 月 31 日に終了した 3 ヶ月間の当社 RSU の活動の概要は以下のとおりです。量職場.職場加重平均贈与日交易会単位あたりの価値2023 年 9 月 30 日現在$パフォーマンスベースの RSU$既得$キャンセルします

$2023年12月31日現在債務未返済$2022 年 12 月 31 日に終了した 3 ヶ月間の RSU は付与されていない。RSU に関連する未認識補償費用は、 2023 年 12 月 31 日現在 33，628 ドルであり、加重された-平均して 期間は 3.9 年です株式オプション本合併に関連して、すべてのレガシーモビックス株式オプションは、行使価格、譲渡条件その他の条件に変更されず、当社によって引き受けられ、同数の株式オプションに転換されました。2023 年 12 月 31 日までの 3 ヶ月間のストックオプション活動は以下のとおりです。量オプション重みをつける—Aヴェラージ

行権価格    1株当たり加重平均残り契約書期限(年)

2023 年 9 月 30 日現在    $授与する$

$期限が切れる$

2023年12月31日現在債務未返済

$2023年12月31日に行使できます$F — 63カタログ表

MOBIX LABS， INC.簡明合併財務諸表付記（ 未監査、千単位、株式および 1 株当たり金額を除く ）注 17 — 株式インセンティブプラン(続)株式オプションの授与条件は、当社の裁量により、株式オプションの行使のための「純株式決済」を許可しています。2023 年 12 月 31 日に終了した 3 ヶ月間に行使された株式オプションには、クラス A 普通株式 168，235 株の合計 390，440 株の購入オプションが含まれ、当社への現金収益はありません。

未認識株式-ベース 2023 年 12 月 31 日現在、ストックオプションに関連する報酬費用は合計 4，963 ドルであり、加重された-平均して 2.3 年の期間です2023 年 12 月 31 日時点の発行済株式オプションと行使可能な株式オプションの本質的価値の合計は、それぞれ 7，587 ドルと 7，587 ドルでした。2023 年 12 月 31 日と 2022 年 12 月 31 日までの 3 ヶ月間に行使されたオプションの本質的価値の総額は、それぞれ $1，639 と $0 でした。2023 年 12 月 31 日と 2022 年 12 月 31 日までの 3 ヶ月間に付与されたオプションの公正価値の合計は、それぞれ 903 ドルと 785 ドルでした。重み付け-平均して 2023 年 12 月 31 日に付与されたオプションの公正価値はそれぞれ 3.50 ドルと 3.60 ドルでした付与されたストックオプションの公正価値は、以下の仮定で推定されました。12 月 31 日までの 3 ヶ月間射程距離射程距離ロー高ロー高予想ボラティリティ期待配当収益率リスクフリー金利所期期間(年)連結営業決算および総合損益計算書には、株式が含まれます。

-ベース 補償費は以下の通り。3 か月終了十二月三十一日収入コスト$

$/研究 · 開発/販売、一般、行政株式に基づく報酬総支出$$注 18 1 株当たり純利益 （ 損失 ）当社は、クラス A およびクラス b の普通株式の 1 株当たり純利益 （ 損失 ） を、 2 株を用いて算出します。-クラスだ 方法だ1 株当たり基本純利益 （ 損失 ） は、加重を使用して計算されます。

期間の発行済株式数1 株当たり希釈純利益 （ 損失 ） は、加重を使用して計算されます。-平均して

株式数および期間の潜在的に希釈可能な有価証券の発行済みの影響。潜在希釈有価証券は、ストックオプション、ワラント、 RSU 、その他の偶発発行株式で構成されます。発行済株式オプション、ワラント、 RSU およびその他の偶発発行株式の希釈効果は、 （ a ） のより希釈したものを適用することにより、 1 株当たり希釈利益に反映されます。-クラスだ メソッドまたは （ b ） if-変換された 方法と財務株式法が適用されますクラス A 普通株式の希釈純損益の計算は、クラス b 普通株式の転換を想定していますが、クラス b 普通株式の希釈純損益は、これらの株式の転換を想定していません。当社が純損失を計上している期間中、 F — 64

カタログ表

MOBIX LABS， INC.    簡明合併財務諸表付記

（ 未監査、千単位、株式および 1 株当たり金額を除く ）

注 18 1 株当たり純利益 （ 損失 ）    (続)重みをつける-平均して

1 株当たり希釈純損失の計算に使用される株式数は、純損失が存在する場合には、希釈証券の影響が反面であるため、計算には含まれないため、基本純損失と同じです。    -希釈剤

3 か月終了

•        十二月三十一日A類

•        クラスBごく普通である

1株当たり基本純収益(損失)：

•        分子：純収益分配

•        $$$分母：加重平均流通株1株当たりの基本純収益$$

•        $1株当たりの純利益(損失)：分子：純収益分配$$$クラス b 普通株式からクラス A 普通株式への転換による純利益の再配分純利益の再配分純収益分配分母：転換優先株式 （ 転換時ベース ）普通株式引受証転換可能な手形

•        F — 65カタログ表

MOBIX LABS， INC.

•        簡明合併財務諸表付記（ 未監査、千単位、株式および 1 株当たり金額を除く ）

注 19 — 濃度    2023 年 12 月 31 日までの 3 ヶ月間、 2 社のお客様が当社の収益の 67% を占めました。2022 年 12 月 31 日までの 3 ヶ月間、 1 社のお客様が売上高の 86% を占めています。他の顧客は、それぞれの期間の収益の 10% を超えませんでした。2023 年 12 月 31 日現在、 1 社のお客様の未払金残高は、当社の売掛金総額の 17% を占めています。2023 年 9 月 30 日現在、 2 社のお客様の未払金残高は、当社売掛金総額の 97% を占めています。注 20 — 地理情報地域別収益船舶による地域別売上高-行くぞ

•         場所は以下の通りです:

•        3 か月終了

•        十二月三十一日

•        $$株式会社エミソリューションズ貸借対照表6月30日まで

•        資産

•        流動資産：

現金

$

$

売掛金

貸付債権 — 株主前払い費用流動資産総額財産·工場·設備·純価値

経営的リース使用権資産

その他の資産    総資産$$負債と株主権益流動負債：売掛金

$$発生経費信用限度額貸付金 — 関連当事者

流動負債総額コミットメントと不測の事態 （ 注 9 ）株主権益：

2023 年 6 月 30 日、 2022 年 6 月 30 日現在発行済普通株式 1，000 万株、発行済発行済普通株式 1，000 株    留保利益株主権益総額総負債と株主権益$$付記はこれらの財務諸表の不可分の一部だ。F—70

カタログ表

株式会社エミソリューションズ

運営説明書

2013年6月30日までの年間

純収入    $$販売原価総利益運営費用：販売、一般、行政減価償却

総運営費    営業損失

その他の収入：    その他の純収入

その他の収入合計，純額

所得税未払いの収入

所得税支給

純収益(赤字)$$付記はこれらの財務諸表の不可分の一部だ。F—71

カタログ表

株式会社エミソリューションズ

株主持分説明書

普通株保持収益.収益合計する株主の株式会社株価

金額

バランス、2021年6月30日

$$$

バランス、2022年6月30日

純収入

バランス、2023年6月30日

$

$$付記はこれらの財務諸表の不可分の一部だ。

カタログ表

株式会社エミソリューションズ

現金フロー表

信用額の下での純借入 （ 支払 ）    融資活動が提供する現金純額

現金純増(マイナス)    現金、年明け

年末現金    $

補足キャッシュフロー開示 ：利子を支払う現金

$    $所得税の現金を納める$

$    付記はこれらの財務諸表の不可分の一部だ。F — 73カタログ表株式会社エミソリューションズ財務諸表付記

2023 年 6 月 30 日および 2022 年    付記1--業務の性質と最近の発展EMI Solutions，Inc.は、カリフォルニア州に本社を置き、軍事および航空宇宙サプライチェーンおよび様々な商業アプリケーションに電磁干渉(“EMIソリューション”)フィルタリング製品を提供する大手小型企業メーカーである。同社の製品には、EMIソリューションフィルタモジュール、フィルタコネクタ、フレキシブルフィルタプラグイン、給電が含まれています-直通だフィルターとケーブルアセンブリです。同社はカリフォルニア州のオーウェンに本社を置いている。Mobix Labs，Inc.と統合する.2022年9月、当社はMobix Labs，Inc.(“Mobix”)と合意を締結し、この合意により、MobixはEMI Solutionsのすべての発行済みおよび発行済み普通株を買収する。買収コストは964，912株を予定しているMobix普通株式と現金2200，000ドルです。対価格の現金部分では、155，000ドルは取引完了時に支払い、残りの部分はMobixの前にChavant Capital Acquisition Corp.と統合された特定の日または20日に支払うことを発表しますASCテーマ：321投資-株式証券当該等の基準は、権益投資(権益会計方法による入金又は被投資者の合併を招く権益投資を除く)を貸借対照表に権益証券として単独で列記し、公正価値に基づいて計量し、公正価値変動を純収益で確認することを要求する。

当社は2022年6月30日までに株式証券へのすべての投資を売却し、2023年6月30日、2023年6月30日および2022年6月30日に、当社は持分証券を保有していない。2023年6月30日と2022年6月30日までの2年間で、株式証券の売却済み収益はそれぞれ0ドルと21，658ドルであり、営業報告書の他の収入(費用)に計上されている。    所得税当社は米国会計基準第740号のテーマに基づいて所得税を計算した所得税

(ASC-740)繰延税金資産および負債は、既存の資産および負債の財務諸表の帳簿金額とそのそれぞれの税務ベースとの間の差によって生じる将来の税務結果として確認される貸借対照法を使用する。税法変更が繰延税項資産や負債に及ぼす影響は新法律公布期間中の経営結果で確認された。繰延税金資産が現金化できない可能性が高い場合、当社は必要に応じて繰延税金資産の帳簿金額を減らすために推定値を設定する。当社が繰延税金資産を実現する能力を評価する際には、当社は歴史的経営業績、持続的な税務計画、および1つの管轄区域の将来の課税所得額の予測を含むすべての利用可能なプラスと負の証拠を考慮する    -押すんだ

-司法管轄権    基礎です。過去の損失水準に基づき、当社は繰延税項目の純資産をより顕在化する可能性のある金額に減らすための評価を確立している。

-手順

識別と測定の過程について。当社は、現地税務機関が税務立場の技術的利点に基づいて審査を行った後にのみ、税務立場を維持することが可能となり、税務優遇を確認することができます。そして、当社は、最終的に関連会社と和解した際に実現する可能性が50%以上の最大利益を基準に、財務諸表から当該等頭寸から確認した税収割引を計測します

F—76

カタログ表株式会社エミソリューションズ財務諸表付記2023 年 6 月 30 日および 2022 年付記2--重大会計政策

-Term

これらの楽器の成熟度。

最近採用された会計公告

2016 年 2 月、 FASb は ASU 2016 を発行した。

リース事業 （トピック 842） （「 ASU 2016 」）ASU 2016 にいくつかのアップデート、修正、技術的改善を発表しました。リース取引の会計に関するガイダンスを提供します基準は、賃借人が権利とともにリース債務を認識することを要求しています。— オフ-使用する.”

1 年以上の期間を持つすべてのリースの資産賃借人は、賃借債務及び関連権利を認識しないために、原資産の種類別に会計方針を選択することが認められます。

— オフ

また、割引率、リース期間、リースから生じるキャッシュフローの金額、時期、不確実性に関するリース取極についての追加開示も求められています。このガイダンスは、修正された遡及法により、 2022 年 7 月 1 日付で施行されました。2022 年 7 月 1 日をもって、当社は

— オフ-3-使用する

バランスシート上の資産と関連するリース負債 169，380 ドルです注記 6— リースを参照。

•        F—77

•        カタログ表

•        株式会社エミソリューションズ$$

•        自動車

•        賃借権改善

•        財産と設備、毛額

•        減算：減価償却累計

•        財産と設備、純額

•        $$2023 年 6 月 30 日期と 2022 年 6 月 30 日期を末日とする年度の資産 · 設備関連減価償却費は、それぞれ 19，985 ドルと 15，941 ドルでした。注記 4— 発生経費計算すべき費用には以下が含まれている

六月三十日

未払い給与と有給休暇

$

•        $

•        クレジットカード

•        発生経費$$

•        以下のリース費用は、 2023 年 6 月 30 日期営業計算書に含まれています。

•        $短期賃貸コスト総賃貸コスト$

•        2023 年 6 月 30 日現在における ROU 資産および営業リース負債に関する情報

レンタル負債の金額を計上するために支払った現金

$

加重平均リース期間 （ 年間 ）

加重平均割引率

•        当社は、 2023 年 6 月 30 日に終了した年度において、新規営業 · ファイナンス · リース債務と引き換えに ROU 資産を取得していません。

•        以下の表は、 2023 年 6 月 30 日現在のバランスシートに計上された営業リース負債との割引なしキャッシュ · フローの調整です。

•        最低賃貸支払総額

•        $

•        計上された利息を差し引く

•        将来の最低レンタル支払いの現在価値

•        リース中の経常債務の減少

長期リース債務

$

F — 79カタログ表株式会社エミソリューションズ財務諸表付記

2023 年 6 月 30 日および 2022 年

注記 6— リース

比較期間の補足情報

2023 年 6 月 30 日に終了した年度のリース費用は 114，600 ドルでした。非営業リースの最低リース支払額—cancelable.

2023 年 6 月 30 日時点での 1 年を超える期間は以下の通りです。

6 月 30 日までの年

$

総額

$

ビルリース

当社は、当社の執行役員を務める株主が所有 · 支配する Alton Properties LLC から本社をリースしています。注記 6— リースを参照。

貸付債権 — 関連当事者当社は、株主が所有する会社に対して支払うべきローンを有しており、そこからカリフォルニア州アーバインの主要なオフィスを賃貸しています。本契約では、当社に対して最大 20 万ドルまでの無担保融資を行い、未払い元本に対する利子は年率 5.0% で毎月支払遅滞となります。2023 年 6 月 30 日、 2022 年 6 月 30 日時点で、ローンの負債額はそれぞれ 82，890 ドルと 65，000 ドルでした。貸付債権 — 株主当社は、主要株主および最高経営責任者に融資を行っています。2023 年 6 月 30 日、 2022 年 6 月 30 日時点で、融資の債権額はそれぞれ 55，577 ドル、 55，577 ドルでした。

注記 8— 所得税

•        所得税の支出には以下の内容が含まれる6 月 30 日終了。

•        現在：連邦制

•        $$

状態.状態総電流延期：

連邦制

状態.状態

集計を延期する

____________

(1)      繰延税金資産の純額は以下のとおりです。六月三十日繰延税金資産：現金$

(2)      売掛金貸付債権 — 株主流動資産総額財産·工場·設備·純価値経営的リース使用権資産

(3)      その他の資産総資産$

(4)      $

負債と株主権益

流動負債：

売掛金

$$発生経費 貸付金 — 関連当事者

賃貸負債を経営し、流動

流動負債総額コミットメントと不測の事態 （ 注 9 ）株主権益： 2023 年 9 月 30 日および 2023 年 6 月 30 日時点で発行済普通株式 1，000，000 株、発行済発行済株式 1，000 株

留保利益

株主権益総額

総負債と株主権益

$

$

F — 83

カタログ表株式会社エミソリューションズ運営簡明報告書(未監査)9 月 30 日までの 3 ヶ月間純収入$$販売原価. 総利益運営費用：販売、一般、行政減価償却総運営費所得税未払いの収入所得税支給

純収益(赤字)

$$

付記はこのような簡明な財務諸表の構成要素である。F — 84 カタログ表 株式会社エミソリューションズ

株主資本の概要説明書

(未監査)普通株保持収益.収益総額株主の株式会社株価

金額バランス、2022年6月30日 $ $

純損失

バランス、 2022 年 9 月 30 日$$$バランス、2023年6月30日$

$$ 純損失 バランス、 2023 年 9 月 30 日 $

$

$付記はこのような簡明な財務諸表の構成要素である。F — 85

カタログ表株式会社エミソリューションズ

現金フロー表の簡明表

____________

賃借権改善

(1)      財産と設備、毛額 減算：減価償却累計財産と設備、純額$

(2)      $ 2023 年 9 月 30 日と 2022 年 9 月 30 日に終了した 3 ヶ月間の資産 · 設備関連減価償却費は、それぞれ 5，60 4 ドルと 3，972 ドルでした。F — 89カタログ表

(3)      株式会社エミソリューションズ 簡明財務諸表付記(未監査)注記 4— 発生経費

(4)      2023年9月30日 六月三十日未払い給与と有給休暇$$所得税に対処する発生経費$

(5)      $ 注 5 — 信用枠

当社は、ウェルズ · ファーゴ銀行と最大 10 万ドルまでの回転借入を提供する信用契約を結んでいます。利息は、銀行のプライム金利 + 175 ベーシスポイント （ 2023 年 9 月 30 日および 2023 年 6 月 30 日時点で 9.0% ） に基づく変動金利で毎月支払われます。クレジットラインはオンデマンドで支払われ、毎年更新の対象となります。2023 年 9 月 30 日または 2023 年 6 月 30 日時点で、クレジットラインの下での借入残高はなく、クレジットラインの下での利用可能な借入残高は 2023 年 9 月 30 日または 2023 年 6 月 30 日時点で 10 万ドルでした。9 月 30 日までの 3 ヶ月間。

リースコストを経営する

$

短期賃貸コスト総賃貸コスト$

2023 年 9 月 30 日現在の ROU 資産および営業リース負債に関する情報 ：レンタル負債の金額を計上するために支払った現金$ 加重平均リース期間 （ 年間 ）

加重平均割引率

当社は、 2023 年 9 月 30 日に終了した 3 ヶ月間において、新規営業 · ファイナンス · リース債務と引き換えに ROU 資産を取得しませんでした。

以下の表は、 2023 年 9 月 30 日時点の縮約バランスシートに計上された営業リース負債との割引なしキャッシュフローの調整です。6 月 30 日までの年数2024 年 （ 残る 3 ヶ月 ）

$最低賃貸支払総額計上された利息を差し引く 将来の最低レンタル支払いの現在価値

長期リース債務

$

比較期間の補足情報

2022 年 9 月 30 日に終了した 3 ヶ月間のリース費用は 28，800 ドルでした。非営業リースの最低リース支払額

—cancelable

2023 年 6 月 30 日時点での 1 年を超える期間は以下の通りです。

6 月 30 日までの年

$

総額$注記 7— 関連当事者の取引ビルリース当社は、当社の執行役員を務める株主が所有 · 支配する Alton Properties LLC から本社をリースしています。注記 6— リースを参照。

貸付債権 — 関連当事者

当社は Alton Properties LLC に支払うべきローンがあります。この契約は、随時修正されており、当社に対して最大 40 万ドルまでの無担保融資を規定しており、未払い元本額に年率 6.5% の利子が支払われ、月間延滞で支払われます。2023 年 9 月 30 日と 2023 年 6 月 30 日の時点で、ローンの負債額はそれぞれ 205，484 ドルと 82，890 ドルでした。F — 91カタログ表

株式会社エミソリューションズ

簡明財務諸表付記

(未監査)

The number of shares available for issuance under the 2023 Equity Incentive Plan will be increased on the first day of each fiscal year beginning with the 2024 fiscal year through and including the first day of the 2033 fiscal year, in each case, in an amount equal to the lesser of (a) 5% of the total number of shares of Class A Common Stock that are issued and outstanding on the first day of the applicable fiscal year, and (b) such smaller number of shares determined by our Board.

2023 Employee Stock Purchase Plan

Set forth below is a summary of the material features of the 2023 Employee Stock Purchase Plan.

Purpose

The 2023 Employee Stock Purchase Plan provides a means by which eligible employees and/or eligible service providers of either us or our affiliate may be given an opportunity to purchase shares of Class A Common Stock. The 2023 Employee Stock Purchase Plan permits us to grant a series of purchase rights to eligible employees and/or eligible service providers. By means of the 2023 Employee Stock Purchase Plan, we will seek to retain and assist our affiliates in retaining the services of such eligible employees and eligible service providers, to secure and retain the services of new eligible employees and eligible service providers and to provide incentives for such persons to exert maximum efforts for our success and that of our affiliates.

Stock Subject to Employee Stock Purchase Plan

Subject to adjustments as provided in the 2023 Employee Stock Purchase Plan, the maximum number of shares of Class A Common Stock that may be issued under the 2023 Employee Stock Purchase Plan will be equal to 858,935, plus the number of shares of Class A Common Stock that are automatically added on the first day of each fiscal year beginning with the 2023 fiscal year through and including the first day of the 2032 fiscal year, in each case, in an amount equal to 1% of the total number of shares of Class A Common Stock issued and outstanding on the first day of applicable fiscal year, unless the Board determines that there will be no increase in the share reserve or that the increase in the share reserve for the applicable fiscal year will be a lesser number of shares of Class A Common Stock than would otherwise occur. If any purchase right granted under the 2023 Employee Stock Purchase Plan terminates without having been exercised in full, the shares of Class A Common Stock not purchased under such purchase right will again become available for issuance under the 2023 Employee Stock Purchase Plan.

Benefits and Perquisites

We provide benefits to our named executive officers on the same basis as provided to all of our employees, including medical, dental, vision, life and AD&D, and short- and long-term disability insurance, vacation and paid holidays. The named executive officers are also eligible to participate in our 401(k) plan.

Director Compensation

In 2021, we entered into board of directors agreements with our non-employee directors, including James Peterson, David Aldrich, Kurt Busch, William Carpou and Frederick Goerner. Under these agreements, we agreed to issue to each director an option to purchase 20,000 shares of Class A Common Stock. The option is subject to a one-year vesting schedule, with 8,000 shares vesting immediately, and the remaining 12,000 shares vesting at the rate of 1,000 shares per month over the 12 consecutive months thereafter, subject to the holder’s continuous service through each vesting date. We also agreed to reimburse the director for any reasonable costs and expenses incurred in connection with the director’s services requested by us and performed by the director. Each agreement will automatically renew on the date of director’s reelection unless the Board determines not to renew the agreement, or until a director’s earlier resignation, removal or death.

Historically, we issued options on an annual basis for each of our non-employee directors. Our non-employee directors have not received any cash compensation for their services as directors and have instead, from time to time, been compensated with awards of options or RSUs in amounts determined by our Board. During the fiscal year ended September 30, 2023, none of the members of the Board received any compensation for their service as a director.

In connection with the Closing, we amended the Board agreement with each of Mr. Peterson and Mr. Goerner. The amendment provides that the director will be granted, on the first, second and third anniversaries of December 21, 2023, RSUs with respect to 166,666 shares of Class A Common Stock, which will vest on the first anniversary of the applicable grant date, subject to his continuous service to Mobix Labs through the applicable grant dates and vesting dates. The RSUs will become fully vested in the event of a change of control, or if the director’s service is terminated either without cause or by him for Good Reason (as defined in the 2022 Plan).

On January 22, 2024, the Board approved non-employee director compensation that is designed to retain competent and experienced persons to serve as members of the Board. Non-employee directors will be entitled to receive an annual cash retainer, which will be payable quarterly and pro-rated for partial quarters, of $200,000 and reimbursement for expenses incurred for attending Board meetings. Non-employee Board members will also be entitled to receive awards under the 2023 Equity Incentive Plan annually and upon their initial appointment to the Board as follows:

•        A one-time grant of 20,000 RSUs to the current non-employee directors;

•        Annual awards of 20,000 RSUs at the next Board meeting occurring after December 21, 2024; and

•        Upon initial election or appointment to the Board, a pro-rated amount of 20,000 RSUs for the partial year.

These RSUs will vest monthly over a period of one year, subject to the director’s continuous service, and will not be delivered until such time as determined by the Board.

In addition, the Board approved, subject to approval of our stockholders, the grant of RSUs to the following non-employee directors who were influential in the public listing of our shares on Nasdaq:

•        James Peterson 1,050,000 RSUs

•        Frederick Goerner 1,050,000 RSUs

•        David Aldrich 50,000 RSUs

•        Kurt Busch 50,000 RSUs

•        William Carpou 50,000 RSUs

DESCRIPTION OF SECURITIES

The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities. The full text of our Charter and amendment to the Charter, which together are referred to as the Charter, and Bylaws is included as Exhibit 3.1, Exhibit 3.2, and Exhibit 3.3 respectively, to the registration statement of which this prospectus forms a part and is incorporated herein by reference. We urge you to read our Charter and Bylaws in their entirety for a complete description of the rights and preferences of our securities.

Authorized and Outstanding Stock

Our Charter authorizes three hundred million (300,000,000) shares, consisting of three (3) classes: (i) two-hundred and eighty-five million (285,000,000) shares of Class A Common Stock, $0.00001 par value per share, (ii) five million (5,000,000) shares of Class B Common Stock, $0.00001 par value per share, and (iii) ten million (10,000,000) shares of Preferred Stock, $0.00001 par value per share.

As of April 30, 2024, there were 24,609,287 shares of Class A Common Stock outstanding, 2,254,901 shares of Class B Common Stock outstanding and no shares of Preferred Stock outstanding.

Voting Power

Holders of Class A Common Stock and holders of Class B Common Stock vote together as a single class on all matters submitted to a vote of the stockholders except as otherwise required by applicable law or the rules or regulations of any stock exchange applicable to Mobix Labs or by or pursuant to the Charter. Holders of Class A Common Stock are entitled to one (1) vote for each share of Class A Common Stock held of record by such holder on all matters to be voted on by stockholders except as otherwise required by applicable law or the rules or regulations of any stock exchange applicable to Mobix Labs or by or pursuant to the Charter. Holders of Class B Common Stock are entitled to ten (10) votes for each share of Class B Common Stock held of record by such holder on all matters to be voted on by stockholders except as otherwise required by applicable law or the rules or regulations of any stock exchange applicable to Mobix Labs or by or pursuant to the Charter.

Dividends and Distribution Rights

Subject to applicable law and the rights, if any, of any holders of any outstanding series of Preferred Stock, holders of Common Stock are entitled to receive dividends or distributions when, as and if declared by the Board in its discretion, payable either in cash, in property or in shares of capital stock. Generally, the holders of Common Stock share in such dividends or distributions ratably in proportion to the number of shares held by them; except that if a dividend or distribution is proposed to be declared and paid or set apart for payment to the holders of Class A Common Stock in shares of Class A Common Stock or rights to acquire shares of Class A Common Stock or to the holders of Class B Common Stock shares of Class B Common Stock or rights to acquire Class B Common Stock, a dividend or distribution of an equal number of shares of Class B Common Stock or rights to acquires Class B Common Stock shall be declared and paid or set apart for payment to the holders of Class B Common Stock or a dividend or distribution of an equal number of shares of Class A Common Stock or rights to acquire shares of Class A Common Stock shall be declared and paid or set apart for payment to the holders of Class A Common Stock, respectively.

Liquidation, Dissolution and Winding Up

Subject to applicable law and the rights, if any, of any holders of any outstanding series of Preferred Stock, in the event of any liquidation, dissolution or winding up, the holders of outstanding shares of Common Stock are entitled to receive pro rata Mobix Labs’ remaining assets available for distribution, ratably in proportion to the number of shares of Common Stock held by them.

Conversion

Each outstanding share of Class B Common Stock may, at the option of the holder thereof at any time upon written notice to Mobix Labs, be converted into one (1) fully-paid and non-assessable share of Class A Common Stock. Each outstanding share of Class B Common Stock will be automatically, without further action by the holder

thereof, converted into one (1) fully-paid and non-assessable share of Class A Common Stock upon the transfer of such share of Class B Common Stock other than to a “permitted transferee” or (b) at 5:00 p.m. New York City time on the first trading day (on the primary stock exchange on which Mobix Labs shares are then listed) after the seventh anniversary date of the Closing Date. “Permitted Transferees” for this purpose means (1) the other holders of Class B Common Stock immediately following the Closing, (2) their immediate family members, (3) entities controlled directly or indirectly by them or their immediate family members, and (4) individual retirement accounts for their exclusive benefit or the benefit of their immediate family members or any trust forming part of the a stock bonus, pension or profit-sharing plan for the exclusive benefit of the employer’s employees or their beneficiaries under Section 401 of the Code in which they or their immediate family members are participants, subject to them or their immediate family members having sole decision making authority as to the Class B Common Stock in such account or trust, including as to the voting of such Class B Common Stock.

Preemptive or Other Rights

Holders of Common Stock will not be entitled to preemptive rights, and Common Stock is not subject to redemption or sinking fund provisions.

Election of Directors

The Charter and the Bylaws provide, except for those directors, if any, elected by the holders of any series of Preferred Stock then outstanding pursuant to the Charter, establish a classified board of directors that is divided into three (3) classes designated as Class I, Class II and Class III, as nearly equal in number as possible, with staggered three-year terms and with each class containing (for so long as there are three Class B Directors then in office) not more than one Class B Director. Only the directors in one class are elected at each annual meeting of Mobix Labs’ stockholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. For so long as any shares of Class B Common Stock remain outstanding, the holders of a majority of the voting power of the shares of Class B Common Stock then outstanding voting as a separate class are entitled to (i) elect three Class B Directors, (ii) remove from office any Class B Director, and (iii) fill any vacancy caused by the death, resignation, disqualification, removal or other cause of any Class B Director.

Mobix Labs’ stockholders will not have the ability to cumulate votes for the election of directors. The Bylaws provide that, other than with respect to Class B Directors or the directors elected by any series of Preferred Stock then outstanding pursuant to the Charter, at all meetings of stockholders held for the election of directors at which a quorum is present, a majority of the votes cast will be sufficient to elect directors; provided, however, that where one or more stockholders have (a) nominated one or more individuals to the Board in compliance with the Bylaws, and such nominees for election exceeds the number of open seats, and (b) not withdrawn such nomination on or prior to the tenth (10th) day preceding the date on which Mobix Labs first gives notice to stockholders of such meeting of stockholders for the election of directors, a plurality of the votes cast will be sufficient to elect.

Preferred Stock

The Charter expressly authorizes the Board to provide for one or more series of Preferred Stock and pursuant to which the Board is authorized to establish the number of shares to be included in each such series, to fix the designation, powers (including voting powers), preferences and relative, participating, optional or other rights (and the qualifications, limitations or restrictions thereof) of the shares of each such series, in each case without further vote or action by the stockholders. The Charter provides that the number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the then outstanding shares of capital stock entitled to vote, without the separate vote of the holders of outstanding shares of Preferred Stock voting as a single class. The Charter provides that except as may otherwise be provided by applicable law or the rules or regulations of any stock exchange applicable to Mobix Labs or by or pursuant to the provisions of the Charter, no holder of any series of Preferred Stock is entitled to any voting powers. The Board is able to, without stockholder approval, create and issue series of Preferred Stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the Common Stock and could have anti-takeover effects. The ability of the Board to issue Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change of control of Mobix Labs or the removal of existing management.

As of the date of this prospectus, there is no Preferred Stock outstanding.

Warrants

As of April 30, 2024 there were 6,000,000 Public Warrants and 3,000,000 Private Placement Warrants outstanding.

Public Warrants

Each whole Public Warrant entitles the registered holder to purchase one (1) share of Class A Common Stock at a price of $5.79 per share, subject to adjustment as discussed below, at any time commencing January 20, 2024, provided that a registration statement under the Securities Act covering shares of Class A Common Stock issuable upon exercise of the Public Warrants is then effective and a current prospectus relating thereto is available (or holders are permitted to exercise their Public Warrants on a cashless basis under the circumstances specified in the Warrant Agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire on December 21, 2028, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

We will not be obligated to deliver any shares of Class A Common Stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A Common Stock underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to us satisfying its obligations described below with respect to registration. No Public Warrant will be exercisable and we will not be obligated to issue shares of Class A Common Stock upon exercise of a Public Warrant unless the shares of Class A Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the registered holder of the Public Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Public Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless, in which case the purchaser of a Unit containing such Public Warrants will have paid the full purchase price for the Unit solely for the shares of Class A Common Stock underlying such Unit. In no event will we be required to net cash settle any Public Warrant.

We registered the shares of Class A Common Stock issuable upon exercise of the Public Warrants in the registration statement relating to the Merger. However, because the Public Warrants will be exercisable until their expiration date of December 21, 2028, in order to comply with the requirements of Section 10(a)(3) of the Securities Act following the consummation of an initial business combination, we will use our best efforts to file with the SEC a registration statement registering, under the Securities Act, the issuance of the shares of Class A Common Stock issuable upon exercise of the Public Warrants. We will use our best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. If any such registration statement has not been declared effective by the 60th business day following the closing of the Merger, holders of the Public Warrants will have the right, during the period beginning on the 61st business day after the Closing and ending upon such registration statement being declared effective by the SEC, and during any other period when we fail to have maintained an effective registration statement covering the shares of Class A Common Stock issuable upon exercise of the Public Warrants, to exercise such warrants on a “cashless basis,” by exchanging the Public Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption). Notwithstanding the above, if the shares of Class A Common Stock are at the time of any exercise of a Public Warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act (or any successor rule), we may, at our option, require holders of Public Warrants who exercise their Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) and (i) in the event we so elect, we will not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the shares of Class A Common Stock issuable upon exercise of the Public Warrants or (ii) if we do not so elect, we agree to use our best efforts to register or qualify for sale the shares of Class A Common Stock issuable upon exercise of the Public Warrants under the applicable blue sky laws of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available.

Redemption of Public Warrants for Cash

We may redeem the Public Warrants in whole and not in part;

•        at a price of $0.01 per warrant;

•        at any time after the Public Warrants become exercisable;

•        upon not less than 30 days’ prior written notice of redemption to each warrant holder;

•        if, and only if, the reported last sale price of the shares of Class A Common Stock equals or exceeds $9.06 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of shares of Class A Common Stock and equity-linked securities for capital raising purposes in connection with the closing of our initial business combination), for any 20 trading days within a 30-day trading period commencing after the Public Warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and

•        if, and only if, there is a current registration statement in effect with respect to the shares of Class A Common Stock underlying such Public Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption, except if the Public Warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.

We have established the penultimate item of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Public Warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Public Warrants, each Public Warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. Any such exercise would not be done on a “cashless” basis and would require the exercising warrant holder to pay the exercise price for each Public Warrant being exercised. However, the price of the Ordinary Share may fall below the $9.06 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a Public Warrant as described under the heading “— Anti-dilution Adjustments” below) as well as the $9.06 (for whole shares) warrant exercise price after the redemption notice is issued. As of the date of this prospectus, the trading price of the shares of Class A Common Stock on Nasdaq has not achieved the $9.06 threshold that would allow us to redeem the Public Warrants.

Redemption Procedures and Cashless Exercise

If we call the Public Warrants for redemption as described above, the Board will have the option to require any holder that wishes to exercise its Public Warrant to do so on a “cashless basis,” by surrendering the Public Warrants for that number of shares of Class A Common Stock equal to the quotient obtained by dividing (x) the product of the number shares of Class A Common Stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below), over the exercise price of the warrants by (y) the fair market value. “Fair market value” means the average reported closing price of the shares of Class A Common Stock as reported during the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the Public Warrants. If our Board takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Class A Common Stock to be received upon exercise of the Public Warrants, including the “fair market value” in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the Public Warrants. If we call the Public Warrants for redemption and our Board does not take advantage of this option, the members of the Sponsor and their permitted transferees would still be entitled to exercise their Private Placement Warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their Public Warrants on a cashless basis, as described in more detail below.

A holder of a Public Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

Anti-Dilution Adjustments

If the number of outstanding shares of Class A Common Stock is increased by a share capitalization payable in shares of Class A Common Stock, or by a split-up of shares of Class A Common Stock or other similar event, then, on the effective date of such share capitalization, split-up or similar event, the number of shares of Class A Common Stock issuable on exercise of each Public Warrant will be increased in proportion to such increase in the outstanding shares of Class A Common Stock.

In addition, if we, at any time while the Public Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of the shares of Class A Common Stock on account of such shares of Class A Common Stock (or other shares of our share capital into which the warrants are convertible), other than (a) as described above, (b) any cash dividend or cash distribution which, when combined on a per share basis with the per share amounts of all other cash dividends and cash distributions paid on the shares of Class A Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of shares of Class A Common Stock issuable on exercise of each Public Warrant), but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share (c) to satisfy the redemption rights of the holders of the shares of Class A Common Stock in connection with a proposed initial business combination, (d) to satisfy the redemption rights of the holders of the shares of Class A Common Stock in connection with a shareholder vote to amend the Existing Charter to modify the substance or timing of our obligation to redeem 100% of the Class A Common Stock if the Company does not complete the initial business combination within the period set forth in the Existing Charter or with respect to any other provisions relating to shareholders’ rights or pre-initial business combination activity or (e) in connection with the redemption of the Public Shares upon our failure to complete an initial business combination, then the Public Warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value (as determined by our Board in good faith) of any securities or other assets paid on each Ordinary Share in respect of such event.

If the number of outstanding shares of Class A Common Stock is decreased by a consolidation, combination, reverse share split or reclassification of shares of Class A Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of shares of Class A Common Stock issuable on exercise of each Public Warrant will be decreased in proportion to such decrease in outstanding shares of Class A Common Stock.

Whenever the number of shares of Class A Common Stock purchasable upon the exercise of the Public Warrants is adjusted, as described above, the Public Warrant exercise price will be adjusted (to the nearest cent) by multiplying such Public Warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A Common Stock purchasable upon the exercise of the Public Warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Class A Common Stock so purchasable immediately thereafter.

In addition, if (x) we issued additional shares of Class A Common Stock or equity-linked securities for capital raising purposes in connection with the Closing at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our Board and, in the case of any such issuance to the Sponsor and the officers and directors of Chavant (collectively, the “Initial Shareholders”) or their affiliates, without taking into account any shares issued to the Sponsor prior to the consummation of the Chavant IPO (the “Founder Shares”) held by such shareholders or their affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity proceeds, and interest thereon, available for funding the initial business combination on the date of Closing (net of redemptions), and (z) the volume weighted average trading price of the shares of Class A Common Stock during the ten (10) trading day period starting on the trading day prior to the Closing Date (such price, the “Market Value”) was below $9.20 per share, the exercise price of the Public Warrants will be

adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger described under “— Redemption of Warrants for Cash” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. As a result of the issuances of shares under the PIPE Subscription Agreements and other agreements in connection with the Closing, we adjusted the exercise price of the Warrants from $11.50 to $5.79 per share and adjusted the redemption trigger price from $18.00 to $9.06 per share.

In case of any reclassification or reorganization of the outstanding shares of Class A Common Stock (other than those described above or that solely affects the par value of such shares of Class A Common Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of the outstanding shares of Class A Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of Mobix Labs as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the Public Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of Class A Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Public Warrants would have received if such holder had exercised their Public Warrants immediately prior to such event.

Other Matters

The Public Warrants were issued in registered form under the Warrant Agreement between Continental Stock Transfer & Trust Company, as warrant agent, and the Company. You should review a copy of the Warrant Agreement, which is filed as an exhibit to the registration statement, for a complete description of the terms and conditions applicable to the Public Warrants. The Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or mistake, and that all other modifications or amendments will require the vote or written consent of the holders of at least 50% of the then-outstanding Public Warrants, and, solely with respect to any amendment to the terms of the Private Placement Warrants, a majority of the then-outstanding Private Placement Warrants.

The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The Public Warrant holders do not have the rights or privileges of holders of shares of Class A Common Stock and any voting rights until they exercise their Public Warrants and receive shares of Class A Common Stock. After the issuance of shares of Class A Common Stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

No fractional shares will be issued upon exercise of the Public Warrants. If, upon exercise of the Public Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the number of shares of Class A Common Stock to be issued to the Public Warrant holder.

The Warrant Agreement provides that any dispute, controversy, or claim, whether in contract of tort, arising or relating to the Warrant Agreement or the enforcement, breach, termination, or validity thereof, shall be submitted to final and binding arbitration in Orange County, California before one neutral and impartial arbitrator, in accordance with the laws of the state of New York. As a result, warrant holders will not be able to pursue litigation in federal or state court against us and instead will be required to pursue such claims through a final and binding arbitration proceeding.

Private Placement Warrants

The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and shares of Class A Common Stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until January 20, 2024, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable so long as they are

held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by us and exercisable by such holders on the same basis as the Public Warrants. As of the date of this registration statement, the initial purchasers of the Private Placement Warrants (or their permitted transferees) continue to hold all of the Private Placement Warrants.

PIPE Warrants

On December 18, 2023, Chavant entered into a subscription agreement with Sage Hill Investors, LLC (“Sage Hill”) (the “Sage Hill PIPE Subscription Agreement”) pursuant to which Sage Hill purchased 1,500,000 shares of Class A Common Stock in cash at a price of $10.00 per share for an aggregate purchase price of $15,000,000, on the terms and subject to the conditions set forth in the Sage Hill PIPE Subscription Agreement. In connection with the execution of the Sage Hill PIPE Subscription Agreement, Legacy Mobix issued to Sage Hill a warrant to purchase 1,500,000 shares of common stock of Legacy Mobix at an exercise price of $0.01 per share (the “Sage Hill Warrant”). We assumed the Sage Hill Warrant in the Merger. Under the terms of the Sage Hill Warrant, Sage Hill will not be entitled to exercise any portion of such warrant without the prior approval of our stockholders. If stockholder approval is obtained, the Sage Hill Warrant will be exercisable to purchase 1,500,000 shares of Class A Common Stock at an exercise price of $0.01.

On December 20, 2023, Chavant entered into a subscription agreement with Joseph J. Gebbia (“Gebbia”) (the “Gebbia PIPE Subscription Agreement”) pursuant to which Gebbia purchased 75,000 shares of our Class A Common Stock in cash at a price of $10.00 per share for an aggregate purchase price of $750,000, on the terms and subject to the conditions set forth in the Gebbia PIPE Subscription Agreement. In connection with the execution of the Gebbia PIPE Subscription Agreement, Legacy Mobix issued to Gebbia a warrant to purchase 150,000 shares of common stock of Legacy Mobix at an exercise price of $0.01 per share (the “Gebbia Warrant”). We assumed the Gebbia Warrant in the Merger. Under the terms of the Gebbia Warrant, Gebbia will not be entitled to exercise any portion of such warrant without the prior approval of our stockholders. If stockholder approval is obtained, the Gebbia Warrant will be exercisable to purchase 150,000 shares of Class A Common Stock at an exercise price of $0.01.

On December 20, 2023, Chavant entered into a subscription agreement with Steven Wright Owens, Jr. (“Owens”) (the “Owens PIPE Subscription Agreement”) pursuant to which Owens purchased 50,000 shares of our Class A Common Stock in cash at a price of $10.00 per share for an aggregate purchase price of $500,000, on the terms and subject to the conditions set forth in the Owens PIPE Subscription Agreement. In connection with the execution of the Owens PIPE Subscription Agreement, Legacy Mobix issued to Owens a warrant to purchase 150,000 shares of common stock of Legacy Mobix at an exercise price of $0.01 per share (the “Owens Warrant,” and collectively with the Sage Hill Warrant and the Gebbia Warrant, the “PIPE Warrants”). Under the terms of the Owens Warrant, Owens will not be entitled to exercise any portion of such warrant without the prior approval of our stockholders. If stockholder approval is obtained, the Owens Warrant will be exercisable for 150,000 shares of Class A Common Stock at an exercise price of $0.01.

Listing of Securities

Mobix Labs’ Common Stock is currently listed on The Nasdaq Global Market, under the symbol “MOBX” and the Public Warrants are currently listed on The Nasdaq Capital Market under the symbol “MOBXW”.

Transfer Agent and Registrar

The transfer agent and registrar for the Common Stock and warrant agent for the Warrants is Continental Stock Transfer & Trust Company.

Anti-Takeover Effects of Provisions of the Charter, the Bylaws and the DGCL

Certain provisions of the Charter, the Bylaws, and the DGCL could make it more difficult to acquire Mobix Labs by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of Mobix Labs to first negotiate with the Board. Mobix Labs believes that the benefits of these provisions outweigh the disadvantages of discouraging certain takeover or acquisition proposals because, among other things, negotiation of these proposals

could result in an improvement of their terms and enhance the ability of the Board to maximize stockholder value. However, these provisions may delay, deter or prevent a merger or acquisition of Mobix Labs that a stockholder might consider is in their best interest or in Mobix Labs’ best interests, including transactions that might result in a premium over the prevailing market price of Class A Common Stock. For additional information, see the section titled “Risk Factors — Delaware law and Mobix Labs’ governing documents contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and that could delay or discourage takeover attempts that stockholders may consider favorable.”

Classified Board of Directors

The Charter and the Bylaws provide that, except for those directors, if any, elected by the holders of any series of Preferred Stock then outstanding pursuant to the Charter, the Board will be divided into three (3) classes of directors, designated as Class I, Class II and Class III, with the classes to be as nearly equal in number as possible, and with each class being elected to a staggered three-year term and with each class containing (for so long as there are three Class B Directors then in office) not more than one Class B Director. As a result, approximately one-third of the Board will be elected each year. The classification of directors will have the effect of making it more difficult and time-consuming for stockholders to change the composition of the Board. The holders of the Class B Common Stock, voting as a separate class, are entitled to elect up to three members of the Board at any given time.

Authorized but Unissued Shares

The authorized but unissued shares of Common Stock and, once created by the Board in accordance with the Charter, authorized but unissued shares of one or more series of Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and, once created by the Board in accordance with the Charter, authorized but unissued shares of one or more series of Preferred Stock could make more difficult or discourage an attempt to obtain control of Mobix Labs by means of a proxy contest, tender offer, merger or otherwise.

Stockholder Action; Special Meetings of Stockholders

The Charter provides that, except as otherwise provided by or pursuant to the Charter (including, without limitation, as to the holders of Class B Common Stock, consenting separately as a single class), Mobix Labs’ stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. Any action to be taken at any meeting of the holders of shares of Class B Common Stock may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by the holders of shares of Class B Common Stock then outstanding having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of Class B Common Stock then outstanding were present and voted and is delivered to Mobix Labs in accordance with the DGCL.

Further, the Charter provides that solely the Chairperson of the Board, the Chief Executive Officer of Mobix Labs, the President of Mobix Labs, or the Board acting pursuant to a resolution adopted by a majority of the whole board may call special meetings of stockholders, and that the Board will call a special meeting of stockholders upon the written request (made in accordance with the Charter and the Bylaws) of the holders of not less than ten percent of the voting power of the outstanding shares of capital stock of Mobix Labs generally entitled to vote on the nomination, question or business for which such special meeting is requested to be called. These provisions might delay the ability of stockholders to force consideration of a proposal or for stockholders controlling a majority of Mobix Labs capital stock to take any action, including the removal of directors.

Advance Notice Requirements for Stockholder Proposals and Director Nominations

The Bylaws provide that stockholders seeking to bring business before Mobix Labs’ annual meeting of stockholders (other than business required by or pursuant to the Charter to be voted on by the holders of a class of capital stock of Mobix Labs, separately as a single class, or by the holders of a series of Preferred Stock, separately as a single class), or to nominate candidates for election as directors at its annual meeting of stockholders, must provide timely notice. To be timely, a stockholder’s notice will need to be delivered to the Secretary of Mobix

Labs at Mobix Labs’ principal executive offices not less than 90 days nor more than 120 days prior to the one-year anniversary of the preceding year’s annual meeting, provided, however, that in the event that no annual meeting was held during the preceding year or the date of the annual meeting is more than 30 days before or more than 70 days after such anniversary date, to be timely, a stockholder’s notice must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the 90th day prior to such annual meeting or, if later, the 10th day following the day on which public announcement of the date of such annual meeting was first made by Mobix Labs. The Bylaws also specify certain requirements as to the form and content of a stockholders’ notice. These provisions may preclude Mobix Labs’ stockholders from bringing matters before its annual meeting of stockholders or from making nominations for directors at its annual meeting of stockholders.

Supermajority Requirements for the Amendment of the Charter and the Bylaws

The Bylaws provide that the Bylaws may be amended or repealed by the Board or by the affirmative vote of the holders of at least 66⅔% in voting power of the then outstanding shares of capital stock of Mobix Labs entitled to vote, voting together as a single class. In addition, the Charter provides that the affirmative vote of the holders of at least 66⅔% of the voting power of the then outstanding shares of capital stock of Mobix Labs generally entitled to vote, voting together as a single class, will be required to amend certain provisions of the Charter, including provisions relating to the classified board, the size of the board, removal of directors, special meetings of stockholders, actions by written consent, and exculpation of directors and officers.

Directors Removed Only for Cause

The Charter provides that, subject to the rights of the holders of any series of Preferred Stock provided by or pursuant to the Charter, no director may be removed from the Board except for cause and only by the affirmative vote of the holders of at least a majority of the voting power of the then outstanding shares of capital stock of Mobix Labs entitled to vote at an election of directors, voting together as a single class.

Board Vacancies

The Charter provides that, subject to applicable law and the rights, if any, of the holders of any class of capital stock of Mobix Labs then outstanding to elect one or more directors or the holders of any series of Preferred Stock then outstanding to elect one or more preferred directors, newly created directorships resulting from an increase in the authorized number of directors or any vacancies on the board of directors will be filled solely and exclusively by a majority of the directors then in office, even if less than a quorum, or by the sole remaining director. Any director so elected will hold office until the expiration of the term of office of the director whom he or she has replaced and until his or her successor will be elected and qualified, subject to such director’s earlier death, resignation, disqualification or removal. No decrease in the number of directors will shorten the term of any incumbent director.

In addition, for so long as any shares of Class B Common Stock remain outstanding, only the holders of a majority of the voting power of the shares of Class B Common Stock then outstanding, voting or consenting as a single class, will be entitled to remove from office any Class B Director and fill any vacancy of any Class B Director.

These provisions prevent a stockholder from increasing the size of the Board and then gaining control of the board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board, but promotes continuity of directors.

Exclusive Forum Selection

The Charter provides, unless Mobix Labs consents in writing to the selection of an alternative forum and to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks jurisdiction, any state or federal court located within the State of Delaware) will be the sole and exclusive forum for: (a) any derivative action or proceeding brought on behalf of Mobix Labs, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer or employee of Mobix Labs to Mobix Labs or the Mobix Labs stockholders, (c) any civil action to interpret, apply or enforce any provision of the DGCL, (d) any civil action to interpret, apply, enforce or determine the validity of the provisions of the Charter or the Bylaws or (e) any action asserting a claim governed by the internal affairs doctrine, in all cases subject to

the court’s having personal jurisdiction over the indispensable parties named as defendants. However, such forum selection provisions will not apply to the resolution of any complaint asserting a cause of action arising under the Securities Act or any action asserting claims arising under the Exchange Act.

The Charter also provides that, unless Mobix Labs consents in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such claims. As noted above, the Charter provides that the federal district courts of the United States will have exclusive jurisdiction over any action asserting a cause of action arising under the Securities Act. Accordingly, there is uncertainty as to whether a court would enforce such provision. Mobix Labs stockholders will not be deemed to have waived Mobix Labs’ compliance with the federal securities laws and the rules and regulations thereunder.

Section 27 of the Exchange Act creates exclusive United States federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As noted above, the Charter provides that the choice of forum provision does not apply to any action asserting claims arising under the Exchange Act. Accordingly, actions by Mobix Labs stockholders asserting claims arising under the Exchange Act or the rules and regulations thereunder must be brought in United States federal court. Mobix Labs stockholders will not be deemed to have waived Mobix Labs’ compliance with the federal securities laws and the regulations promulgated thereunder.

Any person or entity purchasing or otherwise acquiring any interest in shares of Mobix Labs’ capital stock will be deemed to have notice of and consented to the forum selection provisions in the Charter.

The choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with Mobix Labs or its directors, officers, or other employees, which may discourage such lawsuits against Mobix Labs and its directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provisions contained in the Charter to be inapplicable or unenforceable in an action, Mobix Labs may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations, and financial condition.

Section 203 of the Delaware General Corporation Law

Mobix Labs is subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a Delaware corporation that is listed on a national securities exchange or held of record by more than 2,000 stockholders from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that such stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner as summarized below. A “business combination” includes, among other things, certain mergers, asset or stock sales or other transactions together resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation’s outstanding voting stock. Under Section 203 of the DGCL, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

•        before the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

•        upon the consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding those shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or

•        at or after the time the stockholder became an interested stockholder, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least 66⅔% of the outstanding voting stock which is not owned by the interested stockholder.

Under certain circumstances, Section 203 of the DGCL will make it more difficult for a person who would be an “interested stockholder” to effect various business combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring Mobix Labs to negotiate in advance with the Board because the stockholder approval requirement would be avoided if the Board approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder. Section 203 of the DGCL also may have the effect of preventing changes in the Board and may make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.

Limitation on Liability and Indemnification of Directors and Officers

The Bylaws provide that Mobix Labs’ directors and officers will be indemnified and advanced expenses by Mobix Labs to the fullest extent permitted by applicable law. In addition, the Charter provides that Mobix Labs’ directors and officers will not be liable to Mobix Labs or its stockholders for monetary damages for breaches of their fiduciary duty as directors and officers, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL.

The Bylaws will also permit Mobix Labs to purchase and maintain insurance on behalf of any director, officer, employee or agent of Mobix Labs for any liability arising out of his or her status as such, regardless of whether the DGCL would permit indemnification.

These provisions may discourage stockholders from bringing a lawsuit against Mobix Labs directors or officers for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit Mobix Labs and its stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent Mobix Labs pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification and advancement provisions.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to Mobix Labs’ directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore unenforceable.

SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES

Rule 144

A person who has beneficially owned restricted Class A Common Stock or Public Warrants of Mobix Labs for at least six months would be entitled to sell such securities, provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as Mobix Labs was required to file reports) preceding the sale.

Persons who have beneficially owned restricted Class A Common Stock or Public Warrants of Mobix Labs for at least six months but who are our affiliates at the time of, or any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following:

•        1% of the then outstanding shares of Class A Common Stock or Public Warrants; or

•        the average weekly trading volume of Class A Common Stock or Public Warrants of Mobix Labs, as applicable, during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC.

Sales by affiliates of Mobix Labs under Rule 144 are also subject to certain requirements relating to manner of sale, notice and the availability of current public information about Mobix Labs.

Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies

Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination-related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

•        the issuer of the securities that was formerly a shell company has ceased to be a shell company;

•        the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

•        the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and

•        at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC, which was filed on December 28, 2023, reflecting its status as an entity that is not a shell company.

Upon the Closing, we are no longer a shell company; accordingly, once the conditions listed above are satisfied, Rule 144 will become available for the resale of the above-noted restricted securities.

Amended and Restated Registration Rights and Lock-Up Agreement

In connection with the Closing, an Amended and Restated Registration Rights and Lock-Up Agreement was entered into by Mobix Labs and the Holders.

Pursuant to the terms of the Amended and Restated Registration Rights and Lock-Up Agreement, Mobix Labs is obligated, within 45 days of the consummation of Closing to file a registration statement to register the resale of certain securities of Mobix Labs held by the Holders and to use reasonable best efforts to cause the registration statement to become effective as soon as reasonably practical after the initial filing of the registration statement. The Amended and Restated Registration Rights and Lock-Up Agreement also provides the Holders with “piggy-back” registration rights, subject to certain requirements and customary conditions.

Subject to certain exceptions, the Amended and Restated Registration Rights and Lock-Up Agreement further provides that the Founder Equityholders and Legacy Mobix Holders shall not transfer the Founder Shares or the Legacy Mobix Lock-up Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) until (a) with respect to 50% of such shares, for a period ending on the earlier of the one-year anniversary of the Closing Date and the date on which the VWAP of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period following the Closing or (b) with respect to the remaining 50% of such shares, for a period ending on the earlier of the one-year anniversary of the Closing Date and the date on which the VWAP of the Class A Common Stock equals or exceeds $15.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period following the Closing.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information known to the Company regarding the beneficial ownership of shares of Class A Common Stock and Class B Common Stock by:

•        each person who is the beneficial owner of more than 5% of issued and outstanding shares of Class A Common Stock and Class B Common Stock;

•        each of the Company’s named executive officers and directors; and

•        all of the Company’s executive officers and directors as a group.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of shares of Class A Common Stock and Class B Common Stock beneficially owned by a person and the percentage ownership, the Company deemed outstanding shares of Class A Common Stock and Class B Common Stock subject to options and warrants held by that person that are currently exercisable or exercisable within 60 days of April 30, 2024. The Company did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

Unless otherwise indicated, the Company believes that all persons named in the table have sole voting and investment power with respect to all shares of Class A Common Stock and Class B Common Stock beneficially owned by them.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Mobix Labs, Inc., 15420 Laguna Canyon Rd. Suite 100, Irvine, CA 92618.

The percentage ownership of Class A Common Stock and Class B Common Stock is based on 24,609,287 shares of Class A Common Stock and 2,254,901 shares of Class B Common Stock, respectively, outstanding as of April 30, 2024.

____________

*        Less than one percent

(1)      The number of shares of Class A Common Stock beneficially owned by each person or entity includes any shares of Class B Common Stock (which is convertible for Class A Common Stock) beneficially owned by such person or entity.

(2)      Includes 318,204 shares of Class A Common Stock and 125,000 shares of Class B Common Stock held of record by The Battaglia Trust. Fabian Battaglia is Trustee of The Battaglia Trust and may be deemed to have voting and investment power over securities held thereby. Includes options to purchase 323,529 shares of Class A Common Stock exercisable within 60 days of the date of this prospectus.

(3)      Includes (i) 171,146 shares of Class A Common Stock and 125,000 shares of Class B Common Stock held of record by The KSSF Trust, dated November 27, 2012 (the “KSSF Trust”), (2) 73,529 shares of Class A Common Stock held of record by The KSLI Trust, dated December 7, 2012 (the “KSLI Trust”), (iii) 73,529 shares of Class A Common Stock held of record by The SSLI Trust dated December 7, 2012 (“SSLI Trust”). Keyvan Samini is Trustee of The KSSF Trust and The SSLI Trust, and may be deemed to have voting and investment power over securities held thereby. Keyvan Samini’s spouse is the Trustee of The KSLI Trust and may be deemed to have voting and investment power over securities held thereby. Includes options to purchase 323,529 shares of Class A Common Stock exercisable within 60 days of the date of this prospectus.

(4)      Includes options to purchase 36,850 shares of Class A Common Stock exercisable within 60 days of the date of this prospectus.

(5)      Includes options to purchase 153,416 shares of Class A Common Stock exercisable within 60 days of the date of this prospectus.

(6)      Includes 1,241,552 Private Placement Warrants held directly by Dr. Ma and 1,394,101 shares of Class A Common Stock held by the Sponsor. Dr. Ma is the sole member of Chavant Manager LLC, the manager of the Sponsor, and has voting and investment discretion with respect to the shares of Class A Common Stock held of record by the Sponsor. The Sponsor is expected to distribute shares of Class A Common Stock that it holds to its members, subject to applicable lock-up restrictions and applicable law. In any such distribution, Dr. Ma or her controlled affiliates are expected to receive (i) 724,600 shares of Class A Common Stock representing Founder Shares held by the Sponsor (including 40,000 Founder Shares held by the Sponsor that may be allocated by Dr. Ma in her discretion) following the expiration of the Founder Share Lock-Up and (ii) approximately 71,358 shares of Class A Common Stock that are not subject to a lock-up (representing shares received by the Sponsor pursuant to the Sponsor PIPE Subscription Agreement and the Sponsor Warrant). Chavant Capital Partners LLC is the record holder of the shares reported herein. The business address of the Sponsor is 445 Park Avenue, 9th Floor, New York, NY 10022.

(7)      Includes 1,500,000 shares of Class A Common Stock issued to Sage Hill at the Closing pursuant to the Sage Hill PIPE Subscription Agreement. The business address of Sage Hill is 1307 Carter Street, Chattanooga, TN 37402. In addition, the amount shown in the table does not reflect an additional 1,500,000 shares of Class A Common Stock issuable upon exercise of the Sage Hill Warrant, as the exercise of the Sage Hill Warrant is subject to stockholder approval.

SELLING STOCKHOLDER

This prospectus relates to the offer and sale by B. Riley Principal Capital II of up to 9,500,000 shares of our Class A Common Stock that have been and may be issued by us to B. Riley Principal Capital II under the Purchase Agreement. For additional information regarding the shares of our Class A Common Stock included in this prospectus, see the section titled “Committed Equity Facility” above. We are registering the shares of our Class A Common Stock included in this prospectus pursuant to the provisions of the Registration Rights Agreement we entered into with B. Riley Principal Capital II on March 18, 2024 in order to permit the Selling Stockholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement and as set forth in the section titled “Plan of Distribution (Conflict of Interest)” in this prospectus, B. Riley Principal Capital II has not had any material relationship with us within the past three years.

The table below presents information regarding the Selling Stockholder and the shares of our Class A Common Stock that may be resold by the Selling Stockholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Stockholder and reflects holdings as of April 30, 2024. The number of shares in the column “Maximum Number of Shares of Class A Common Stock to be Offered Pursuant to this Prospectus” represents all of the shares of our Class A Common Stock being offered for resale by the Selling Stockholder under this prospectus. The Selling Stockholder may sell some, all or none of the shares being offered for resale in this offering. We do not know how long the Selling Stockholder will hold the shares before selling them and, except as set forth in the section titled “Plan of Distribution (Conflict of Interest)” in this prospectus, we are not aware of any existing arrangements between the Selling Stockholder and any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Class A Common Stock being offered for resale by this prospectus.

Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of our Class A Common Stock with respect to which the Selling Stockholder has sole or shared voting and investment power. The percentage of shares of our Class A Common Stock beneficially owned by the Selling Stockholder prior to the offering shown in the table below is based on an aggregate of 24,609,287 shares of our Class A Common Stock outstanding on April 30, 2024. Because the purchase price to be paid by the Selling Stockholder for shares of our Class A Common Stock, if any, that we may elect to sell to the Selling Stockholder in one or more VWAP Purchases and one or more Intraday VWAP Purchases from time to time under the Purchase Agreement will be determined on the applicable Purchase Dates therefor, the actual number of shares of our Class A Common Stock that we may sell to the Selling Stockholder under the Purchase Agreement may be fewer than the number of shares being offered for resale under this prospectus. The fourth column assumes the resale by the Selling Stockholder of all of the shares of our Class A Common Stock being offered for resale pursuant to this prospectus.

___________

(1)      In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that B. Riley Principal Capital II may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of B. Riley Principal Capital II’s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Market Open Purchases and the Intraday Purchases of our Class A Common Stock under the Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our Class A Common Stock to B. Riley Principal Capital II to the extent such shares, when aggregated with all other shares of our Class A Common Stock then beneficially owned by B. Riley Principal Capital II, would cause B. Riley Principal Capital II’s beneficial ownership of our Class A Common Stock to exceed the 4.99% Beneficial Ownership Limitation. The Purchase Agreement also prohibits us from issuing or

selling shares of our Class A Common Stock under the Purchase Agreement in excess of the 19.99% Exchange Cap, unless we obtain stockholder approval to do so, or unless the average price for all shares of our Class A Common Stock purchased by B. Riley Principal Capital II under the Purchase Agreement equals or exceeds $2.10 per share, such that the Exchange Cap limitation would not apply under applicable Nasdaq rules. Neither the Beneficial Ownership Limitation nor the Exchange Cap (to the extent applicable under Nasdaq) may be amended or waived under the Purchase Agreement.

(2)      Applicable percentage ownership is based on 24,609,287 shares of our Class A Common Stock outstanding as of April 30, 2024.

(3)      Assumes the sale of all shares of our Class A Common Stock being offered for resale pursuant to this prospectus.

(4)      The business address of B. Riley Principal Capital II, LLC (“BRPC II”) is 11100 Santa Monica Blvd., Suite 800, Los Angeles, California 90025. BRPC II’s principal business is that of a private investor. BRPC II is a wholly-owned subsidiary of B. Riley Principal Investments, LLC (“BRPI”). As a result, BRPI may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II. B. Riley Financial, Inc. (“BRF”) is the parent company of BRPC II and BRPI. As a result, BRF may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II and indirectly beneficially owned by BRPI. Bryant R. Riley is the Co-Chief Executive Officer and Chairman of the Board of Directors of BRF. As a result, Bryant R. Riley may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II and indirectly beneficially owned by BRPI. Each of BRF, BRPI and Bryant R. Riley expressly disclaims beneficial ownership of the securities of the company held of record by BRPC II, except to the extent of its/his pecuniary interest therein. We have been advised that none of BRF, BRPI or BRPC II is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) or an independent broker-dealer; however, each of BRF, BRPI, BRPC II and Bryant R. Riley is an affiliate of B. Riley Securities, Inc. (“BRS”), a registered broker-dealer and FINRA member, and Bryant R. Riley is an associated person of BRS. BRS will act as an executing broker that will effectuate resales of our Class A Common Stock that have been and may be acquired by BRPC II from us pursuant to the Purchase Agreement to the public in this offering. See “Plan of Distribution (Conflict of Interest)” for more information about the relationship between BRPC II and BRS.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Related Party Transactions Policy

The Board has adopted a written related party transactions policy that requires that related party transactions (as defined below) be reviewed and, if appropriate, approved by the Board’s audit committee, subject to certain exceptions. Our related party transactions policy is designed to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time.

A “related party transaction” is a transaction, arrangement or relationship in which the Company or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related party had, has or will have a direct or indirect material interest. A “related party” means:

•        any person who is, or at any time during the applicable period was, one of the Company’s executive officers or one of the Company’s directors;

•        any person who is known by the Company to be the beneficial owner of more than 5% of the Company’s voting securities; and

•        any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, executive officer or a beneficial owner of more than 5% of the Company’s voting securities, and any person (other than a domestic employee) sharing the household of such director, executive officer or beneficial owner of more than 5% of the Company’s voting securities.

Pre-Merger Related Party Transactions

Promissory Note

On August 6, 2020, Legacy Mobix borrowed a total of $250,000 from Mr. Giuseppe Battaglia, who is the brother of Mr. Fabian Battaglia, the Company’s Chief Executive Officer, under an unsecured promissory note bearing interest at 12%, compounded annually, through its September 7, 2020 maturity date. On September 3, 2020, the note was converted into a subscription agreement whereby Mr. Giuseppe Battaglia received 490,196 shares (28,835 shares after giving effect to a 1:17 reverse stock split on February 1, 2021) for his loan of $250,000.

On December 8, 2021, Legacy Mobix borrowed a total of $525,000 from Mr. Giuseppe Battaglia under an unsecured promissory note bearing interest at 6%, compounded annually, through its February 21, 2022 maturity date. This note has been fully repaid.

On April 22, 2022, Legacy Mobix borrowed a total of $400,000 from Mr. Giuseppe Battaglia, under an unsecured promissory note bearing interest at 18%, compounded annually, through its June 30, 2022 maturity date. The proceeds from the note were used for general corporate purposes. As of December 31, 2023, the principal balance and interest were paid off in full.

Additionally, on August 3, 2023, Legacy Mobix issued a promissory note having a principal balance of $100,000 to Mr. James Peterson, the company’s director. The note, which matured on August 22, 2023, did not bear interest and was unsecured. In connection with the note, Legacy Mobix agreed to issue the purchaser warrants to purchase 2,924 shares of Legacy Mobix Common Stock at an exercise price of $6.84 per share.

Equity Financing

In February 2021, in connection with the offer and sale of Legacy Mobix Series A Preferred Stock, Legacy Mobix issued 1,449,276 shares of Legacy Mobix Series A Preferred Stock at a purchase price of $1.38 per share for an aggregate purchase price of approximately $2,000,001 and an option (the “Peterson Option”) to purchase an aggregate of 1,796,408 shares of the Legacy Mobix Common Stock at a purchase price of $1.67 per share to Mr. James Peterson, the company’s director. Additionally, Legacy Mobix issued 217,392 shares of Legacy Mobix Series A Preferred Stock at a purchase price of $1.38 per share for an aggregate purchase price of approximately $300,001 and an option (the “Goerner Option”) to purchase an aggregate of 239,521 shares of Legacy Mobix Common Stock at a purchase price of $1.67 per share to Mr. Frederick Goerner, the company’s director.

In multiple closings in 2021, Legacy Mobix entered into various subscription agreements pursuant to which Legacy Mobix issued an aggregate of: (i) 2,059,566 shares of Legacy Mobix Common Stock for an aggregate purchase price of $4,100,001 to Mr. Peterson, which included the exercise of the Peterson Option, and (ii) 263,445 shares of Legacy Mobix Common Stock for an aggregate purchase price of $500,002 to Mr. Goerner, which included the exercise of the Goerner Option.

In 2022, Legacy Mobix entered into subscription agreements with Mr. Elijah Gautney, Mr. Peterson’s son, and Mr. Peterson. Pursuant to each of these subscription agreements, Legacy Mobix issued 14,619 and 153,508 shares of Legacy Mobix Common Stock at a purchase price of $6.84 per share for an aggregate purchase price of $99,993.96 and $1,049,994.72 to Mr. Gautney and Mr. Peterson, respectively.

Additionally, in 2022, Legacy Mobix entered into subscription agreements with each of Mr. Don Goerner, Mr. Jason Goerner and Ms. Sara Van Klaveren, who are the brother, son and daughter, respectively, of a Legacy Mobix’s director, Mr. Frederick Goerner. Pursuant to each of these subscription agreements, Legacy Mobix issued 1,000 shares of Legacy Mobix Common Stock to each of Mr. Don Goerner, Mr. Jason Goerner and Ms. Sara Van Klaveren at a purchase price of $6.84 per share for an aggregate purchase price of $68,400 for each of them.

Stockholder Agreements

In connection with the subscription agreements entered into by Mr. Peterson and Mr. Goerner, Legacy Mobix entered into a stockholder agreement and a voting agreement with each of Mr. James Peterson and Mr. Goerner. The stockholder agreement provided for customary rights of first refusal and co-sale in respect of certain sales of Legacy Mobix Common Stock. The parties to the voting agreement agreed to vote in a certain way on certain matters, including but not limited to, the election of directors of Legacy Mobix and to increase the number of authorized shares of capital stock as approved by the Legacy Mobix Board. Both the stockholder agreement and voting agreement also provided for certain drag-along rights in connection with the sale of Legacy Mobix. All of these rights and the respective agreements terminated in connection with the Closing.

SAFE Agreement

In April 2022, Legacy Mobix entered into a SAFE agreement with Mr. James Aralis pursuant to which Legacy Mobix received funding of $150,000 in exchange for agreement to issue Mr. Aralis shares of Legacy Mobix Capital Stock upon the occurrence of certain events. The number of shares issuable upon conversion is dependent upon a number of factors, including the prices at which Legacy Mobix may sell its equity securities in the future, the Legacy Mobix’s capitalization and the occurrence of certain events. The SAFE also requires cash settlement by Legacy Mobix in certain circumstances, such as in the event of a liquidation or dissolution of Legacy Mobix.

Indemnification

Legacy Mobix has entered into indemnification agreements with Mr. Fabian Battaglia, its Chief Executive Officer and Mr. Keyvan Samini, its Chief Financial Officer, and Mobix Labs entered into new indemnification agreements, with each of its directors and executive officers. The indemnification agreements provide that Mobix Labs will indemnify each of its directors and executive officers against any and all expenses incurred by that director or executive officer because of his or her status as a director or officer of Mobix Labs, to the fullest extent permitted by Delaware law, the Charter and the Bylaws.

The Charter of Mobix Labs contains a provision limiting the liability of directors and certain officers of Mobix Labs for monetary damages for breach of fiduciary duty, and the Bylaws provide that Mobix Labs will indemnify each of its present and former directors and officers in those capacities or for serving other business enterprises at its request, to the fullest extent permitted under Delaware law. In addition, the Bylaws provide that, to the fullest extent permitted by Delaware law, Mobix Labs will advance all expenses incurred by its present and former directors and officers in connection with a legal proceeding involving his or her status as a director or officer of Mobix Labs, except that present directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

Guarantee of Loan

On October 19, 2023, Legacy Mobix borrowed $150,000 from an unrelated finance company, which loan is secured by substantially all assets of Legacy Mobix and is guaranteed by Keyvan Samini, the President, Chief Financial Officer, General Counsel and a director of Mobix Labs. The loan matures in November 2024, with principal and interest payable in weekly installments. Legacy Mobix is obligated to pay a finance charge of $66,000 over the term of the loan.

Subscription Agreement

On December 19, 2023, Chavant entered into a subscription agreement with Michael Long, who was appointed as a director of Mobix Labs on January 22, 2024, pursuant to which Mr. Long agreed to purchase, in a private placement that closed substantially concurrently with the Closing, 300,000 shares of Class A Common Stock at a price of $10.00 per share for an aggregate purchase price of $3,000,000, on the terms and subject to the conditions set forth in the subscription agreement. Mobix Labs has agreed to register for resale the shares received by Mr. Long pursuant to the subscription agreement and upon exercise of the warrant. Pursuant to the subscription agreement, Mobix Labs agreed to issue additional shares of Class A Common Stock to Mr. Long in the event that the Adjustment Period VWAP during the Adjustment Period is less than $10.00 per share. In such case, Mr. Long will be entitled to receive a number of Make-Whole Shares equal to the product of (x) the number of shares of Class A Common Stock issued to Sage Hill at the closing of the subscription and held by Sage Hill through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP. In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

In connection with the execution of the subscription agreement, Legacy Mobix issued to Mr. Long a warrant to purchase 100,000 shares of Mobix Labs Stock at an exercise price of $0.01 per share, exercisable upon the closing of the subscription agreement. The warrant was exercised at the closing of the subscription agreement and, following net settlement into 99,900 shares of Mobix Labs Stock, converted into 99,900 shares of Class A Common Stock in connection with the Closing.

Pre-Merger Related Party Transactions of Chavant

Founder Shares

On April 7, 2021, Chavant issued 2,875,000 Founder Shares to the Sponsor, for which the Sponsor paid $25,000. The Sponsor agreed to forfeit up to 375,000 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters. On June 25, 2021, the Sponsor sold an aggregate of 422,581 of such Founder Shares to the underwriters for a purchase price of $3,675. On July 19, 2021, Chavant reduced the offering size of the Chavant IPO and 575,000 Founder Shares were surrendered to Chavant for cancellation for no consideration, resulting in 2,300,000 Founder Shares outstanding. On September 5, 2021, the underwriters’ over-allotment option expired unexercised, resulting in the forfeiture of an additional 300,000 Founder Shares. As a result, a total of 2,000,000 Founder Shares remained outstanding, which represented 20% of the issued and outstanding Ordinary Shares. All share and per share amounts were retroactively restated.

Chavant’s Initial Shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (i) one year after the completion of the initial Transaction or (ii) the date following the completion of the initial Transaction on which Chavant completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their Ordinary Shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Transaction, the Founder Shares will be released from the lockup. In connection with the Closing, the Amended and Restated Registration Rights Agreement superseded the foregoing arrangements.

Private Placement Warrants

Simultaneously with the closing of the Chavant IPO, pursuant to a Private Placement Warrants Purchase Agreement, dated July 19, 2021, by and between Chavant and the Sponsor, and another Private Placement Warrants Purchase Agreement, dated July 19, 2021, by and between Chavant and the Representatives’ designees, Chavant completed the private sale of 3,400,000 Private Placement Warrants to the Sponsor and the Representatives’ designees at a purchase price of $1.00 per Private Warrant, generating gross proceeds to Chavant of $3,400,000. The Private Placement Warrants are identical to the Public Warrants included as part of the 8,000,000 units sold in the Chavant IPO, except that the Private Placement Warrants, so long as they are held by the initial purchasers or their permitted transferees, (i) are not redeemable by Chavant, (ii) may not (including the Ordinary Shares issuable upon exercise of the warrants), subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of Chavant’s initial business combination, (iii) may be exercised on a cashless basis and (iv) are entitled to registration rights. No underwriting discounts and commissions were paid with respect to such sale. The issuance of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Registration Rights

On the Closing Date, in connection with the Closing and as contemplated by the Business Combination Agreement, the Company, the Sponsor, the Representatives and their designees, certain equityholders of Chavant (collectively with the Sponsor, the “Founder Equityholders”) and certain equityholders of Mobix Labs (the “Legacy Mobix Holders” and, together with the Founder Equityholders and certain other holders, the “Holders”) entered into the Amended and Restated Registration Rights and Lock-Up Agreement, pursuant to which, among other things, the Company is obligated to file a registration statement to register the resale of certain securities of Mobix Labs held by the Holders and to use reasonable best efforts to cause the registration statement to become effective as soon as reasonably practical after the initial filing of the registration statement. The Amended and Restated Registration Rights and Lock-Up Agreement also provides the Holders with “piggy-back” registration rights, subject to certain requirements and customary conditions.

Subject to certain exceptions, the Amended and Restated Registration Rights and Lock-Up Agreement further provides the Founder Equityholders and Legacy Mobix Holders shall not transfer their Common Stock until (a) with respect to 50% of such shares, for a period ending on the earlier of the one-year anniversary of the Closing Date and the date on which the VWAP of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period following the Closing or (b) with respect to the remaining 50% of such shares, for a period ending on the earlier of the one-year anniversary of the Closing Date and the date on which the VWAP of the Class A Common Stock equals or exceeds $15.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period following the Closing.

Administrative Services

Chavant paid the Sponsor $10,000 per month for office space, and secretarial and administrative services provided to members of Chavant’s management team prior to the Closing. Upon completion of the Merger, Chavant ceased paying these monthly fees.

For the nine months ended September 30, 2023 and 2022, Chavant incurred expenses of $90,000 and $90,000 under the administrative services agreement, respectively, of which $150,000 and $80,000 were included in accrued expenses as of September 30, 2023 and December 31, 2022, respectively.

Related Party Notes

On April 7, 2021, Chavant issued an unsecured promissory note to the Sponsor, pursuant to which Chavant could borrow up to an aggregate principal amount of $200,000 to cover formation and operating expenses related to the Chavant IPO. The outstanding balance of $129,602 as of June 30, 2021 was repaid on July 22, 2021. On June 20, 2022, Chavant issued an unsecured convertible promissory note in the aggregate principal amount of

$360,000 to the Sponsor under which Chavant may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. On July 18, 2022, Chavant issued an additional unsecured convertible promissory note in the aggregate principal amount of $490,000 to the Sponsor under which Chavant may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. On January 6, 2023, Chavant issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor, under which Chavant was permitted to draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. Chavant drew down the full amount of the Working Capital Loans under such promissory note. As of September 30, 2023, Chavant had drawn down $1,150,000 under the Working Capital Loans. The Chairman of the Board or an entity affiliated with him and another existing investor in the Sponsor and/or persons affiliated with such investor provided the funds to the Sponsor for the foregoing Working Capital Loans. On June 22, 2023, Chavant issued an unsecured non-convertible note in the aggregate principal amount of up to $500,000 to its Sponsor under which Chavant was permitted to draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. The Chairman of the Board or an entity affiliated with him and the Chief Executive Officer of Chavant provided or will provide the funds to the Sponsor for the Working Capital Loans under this unsecured non-convertible promissory note. As of November 1, 2023, Chavant had drawn down an aggregate of $1,550,000 of Working Capital Loans under the promissory notes issued to the Sponsor (of which $100,000 was received on November 2, 2023).

Sage Hill PIPE Subscription Agreement and Sage Hill Warrant

On December 18, 2023, Chavant entered into the Sage Hill PIPE Subscription Agreement with Sage Hill, pursuant to which Sage Hill agreed to purchase, in a private placement that closed substantially concurrently with the Closing, 1,500,000 shares of Class A Common Stock in cash at a price of $10.00 per share for an aggregate purchase price of $15,000,000, on the terms and subject to the conditions set forth in the Sage Hill PIPE Subscription Agreement. Pursuant to the Sage Hill Subscription Agreement, Chavant agreed to issue additional shares of Class A Common Stock to Sage Hill in the event that the volume weighted average price per share of the Class A Common Stock during the 30-day period (the “Adjustment Period”) commencing on the date that is 30 days after the date on which a resale registration statement is declared effective (the “Adjustment Period VWAP”) is less than $10.00 per share. In such case, Sage Hill will be entitled to receive Make-Whole Shares. In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

In connection with the execution of the Sage Hill PIPE Subscription Agreement, Mobix Labs issued to Sage Hill a warrant to purchase 1,500,000 shares of Mobix Labs Stock at an exercise price of $0.01 per share, exercisable upon the closing of the Sage Hill PIPE Subscription Agreement and stockholder approval (the “Sage Hill Warrant”). The Sage Hill Warrant remains outstanding, and stockholder approval for the exercise of the Sage Hill Warrant is expected to be obtained in 2024.

Sponsor PIPE Subscription Agreement, Sponsor Warrant and Sponsor Letter Agreement

On December 19, 2023, Chavant entered into the subscription agreement (the “Sponsor PIPE Subscription Agreement”) with the Sponsor pursuant to which the Sponsor agreed to purchase, in a private placement that closed substantially concurrently with the Closing, 199,737 shares of Class A Common Stock at a price of $10.00 per share for an aggregate purchase price of $1,997,370 paid through the forgiveness of the Forgiven Chavant Obligations (as defined below), on the terms and subject to the conditions set forth in the Sponsor PIPE Subscription Agreement and the Sponsor Letter Agreement described below. Pursuant to the Sponsor PIPE Subscription Agreement, Chavant agreed to issue additional shares of Class A Common Stock to the Sponsor or its permitted transferees in the event that the Adjustment Period VWAP during the Adjustment Period is less than $10.00 per share. In such case, the Sponsor or its permitted transferees will be entitled to receive Make-Whole Shares. In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.

In connection with the execution of the Sponsor PIPE Subscription Agreement, Legacy Mobix issued to the Sponsor a warrant to purchase 272,454 shares of Mobix Labs Stock at an exercise price of $0.01 per share, exercisable upon the closing of the Sponsor PIPE Subscription Agreement (the “Sponsor Warrant”). The Sponsor Warrant was exercised at the closing of the Sponsor PIPE Subscription Agreement and, following net settlement into 272,182 shares of Mobix Labs Stock, converted into 272,182 shares of Class A Common Stock in connection with the Closing.

On December 20, 2023, Chavant also entered into a Sponsor Letter Agreement with the Sponsor (the “Sponsor Letter Agreement”). Pursuant to the Sponsor Letter Agreement, as consideration for the 199,737 shares issued pursuant to the Sponsor PIPE Subscription Agreement, the Sponsor agreed to forgive, effective upon the Closing, approximately $1,997,370 of aggregate outstanding obligations of Chavant owed to the Sponsor, consisting of (i) $1,150,000 aggregate principal amount of working capital loans outstanding under Chavant’s convertible promissory notes issued to the Sponsor, (ii) $610,000 aggregate principal amount of working capital loans outstanding under Chavant’s non-convertible promissory notes issued to the Sponsor (the accrued interest under which was forgiven), (iii) an estimated additional $40,000 in aggregate principal amount of working capital loans incurred to pay additional expenses in connection with the Closing, (iv) approximately $165,000 of outstanding reimbursement obligations owed to the Sponsor by Chavant for administrative services, as described above and (v) approximately $32,370 of reimbursement obligations owed to Dr. Jiong Ma, the Chief Executive Officer of Chavant, by Chavant for certain operating expenses of Chavant paid by Dr. Ma (collectively, the “Forgiven Chavant Obligations”).

In addition, pursuant to the Sponsor Letter Agreement, the Sponsor agreed to forfeit (1) 658,631 Founder Shares that it held (“Sponsor Forfeited Founder Shares”) and (2) 400,000 Private Placement Warrants that it held (“Sponsor Forfeited Private Placement Warrants”), in each case upon the Closing.

The forfeiture of the Sponsor Forfeited Founder Shares reduced the number of Founder Shares held by the Sponsor, which are subject to the lock-up agreement applicable to the Founder Equityholders as set forth in the Amended and Restated Registration Rights and Lock-Up Agreement (the “Founder Share Lock-Up”), to 922,182 Founder Shares. Mobix Labs expects that the Sponsor will distribute these Founder Shares to its members following the Closing and the expiration of the Founder Share Lock-Up. In such distributions, (1) Dr. Ma or her controlled affiliate is expected to receive (i) 724,600 shares of Class A Common Stock representing Founder Shares (including 40,000 Founder Shares held by the Sponsor that may be allocated by Dr. Ma in her discretion), and (2) Dr. André-Jacques Auberton-Hervé, Chavant’s Chairman, or his controlled affiliate is expected to receive (i) 197,582 shares of Class A Common Stock representing Founder Shares. The forfeiture of the Sponsor Forfeited Private Placement Warrants reduced the number of Private Placement Warrants held by the Sponsor to 2,394,332 Private Placement Warrants. None of the Private Placement Warrants are subject to the Founder Share Lock-Up, and the Sponsor distributed these Private Placement Warrants to its members on December 21, 2023 following the Closing. In such distribution, (ii) Dr. Ma or her controlled affiliate received 1,241,552 Private Placement Warrants, and (ii) Dr. Auberton-Hervé or his controlled affiliate received 358,324 Private Placement Warrants. In addition, the shares of Class A Common Stock the Sponsor received upon the Closing pursuant to the Sponsor PIPE Subscription Agreement and the conversion of the Sponsor Warrant, as described above, are not subject to the Founder Share Lock-Up. Mobix Labs expects that the Sponsor will distribute those shares to its members after the Closing. In such distribution, (1) Dr. Ma or her controlled affiliate is expected to receive approximately 71,399 shares of Class A Common Stock (reflecting $140,000 of non-convertible debt that Dr. Ma had funded or would fund to the Sponsor in respect of working capital loans to Chavant, Dr. Ma’s pro rata share in amount of approximately $130,000 of the outstanding reimbursement obligations owed to the Sponsor for administrative services, and the outstanding reimbursement obligations of $32,370 owed to Dr. Ma, as described above, each forgiven pursuant to the Sponsor Letter Agreement) and (2) Dr. Auberton-Hervé or his controlled affiliate is expected to receive approximately 343,384 shares of Class A Common Stock (reflecting $1.4 million of convertible and non-convertible debt that Dr. Auberton-Hervé had funded to the Sponsor in respect of working capital loans to Chavant and Dr. Auberton-Hervé’s pro rata share of the outstanding reimbursement obligations owed to the Sponsor for administrative services, each forgiven pursuant to the Sponsor Letter Agreement).

PLAN OF DISTRIBUTION (CONFLICT OF INTEREST)

The shares of our Class A Common Stock offered by this prospectus are being offered by the Selling Stockholder, B. Riley Principal Capital II, LLC. The shares may be sold or distributed from time to time by the Selling Stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the shares of our Class A Common Stock offered by this prospectus could be effected in one or more of the following methods:

•        ordinary brokers’ transactions;

•        transactions involving cross or block trades;

•        through brokers, dealers, or underwriters who may act solely as agents;

•        “at the market” into an existing market for our Class A Common Stock;

•        in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;

•        in privately negotiated transactions; or

•        any combination of the foregoing.

In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state’s registration or qualification requirement is available and complied with.

B. Riley Principal Capital II is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.

B. Riley Principal Capital II has informed us that it presently anticipates using, but is not required to use, B. Riley Securities, Inc. (“BRS”), a registered broker-dealer and FINRA member and an affiliate of B. Riley Principal Capital II, as a broker to effectuate resales, if any, of our Class A Common Stock that it may acquire from us pursuant to the Purchase Agreement, and that it may also engage one or more other registered broker-dealers to effectuate resales, if any, of such Class A Common Stock that it may acquire from us. Such resales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. B. Riley Principal Capital II has informed us that each such broker-dealer it engages to effectuate resales of our Class A Common Stock on its behalf, excluding BRS, may receive commissions from B. Riley Principal Capital II for executing such resales for B. Riley Principal Capital II and, if so, such commissions will not exceed customary brokerage commissions.

B. Riley Principal Capital II is an affiliate of BRS, a registered broker-dealer and FINRA member, which will act as an executing broker that will effectuate resales of our Class A Common Stock that may be acquired by B. Riley Principal Capital II from us pursuant to the Purchase Agreement to the public in this offering. Because B. Riley Principal Capital II will receive all the net proceeds from such resales of our Class A Common Stock made to the public through BRS, BRS is deemed to have a “conflict of interest” within the meaning of FINRA Rule 5121. Consequently, this offering will be conducted in compliance with the provisions of FINRA Rule 5121, which requires that a “qualified independent underwriter,” as defined in FINRA Rule 5121, participate in the preparation of the registration statement that includes this prospectus and exercise the usual standards of “due diligence” with respect thereto. Accordingly, we have engaged Seaport Global Securities LLC, a registered broker-dealer and FINRA member (“Seaport”), to be the qualified independent underwriter in this offering and, in such capacity, participate in the preparation of the registration statement that includes this prospectus and exercise the usual standards of “due diligence” with respect thereto. B. Riley Principal Capital II has agreed to pay Seaport a cash fee of $50,000 upon the completion of this offering as consideration for its services and to reimburse Seaport up to $5,000 for expenses incurred in connection with acting as the qualified independent underwriter in this offering. In accordance with FINRA Rule 5110, such cash fee and expense reimbursement to be paid to Seaport for acting as the qualified independent underwriter in this offering are deemed to be underwriting compensation in connection with sales of our Class A Common Stock by B. Riley Principal Capital II to the public. Seaport will receive no other compensation

the Securities Act that may arise from certain written information furnished to us by B. Riley Principal Capital II specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

We estimate that the total expenses for the offering will be approximately $326,300.

B. Riley Principal Capital II has represented to us that at no time prior to the date of the Purchase Agreement has B. Riley Principal Capital II, its sole member, any of their respective officers, or any entity managed or controlled by B. Riley Principal Capital II or its sole member, engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Class A Common Stock or any hedging transaction, which establishes a net short position with respect to our Class A Common Stock. B. Riley Principal Capital II has agreed that during the term of the Purchase Agreement, none of B. Riley Principal Capital II, its sole member, any of their respective officers, or any entity managed or controlled by B. Riley Principal Capital II or its sole member, will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity.

We have advised the Selling Stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.

This offering will terminate on the date that all shares of our Class A Common Stock offered by this prospectus have been sold by the Selling Stockholder.

Our Class A Common Stock is currently listed on Nasdaq under the symbol “MOBX”.

B. Riley Principal Capital II and/or one or more of its affiliates has provided, currently provides and/or from time to time in the future may provide various investment banking and other financial services for us and/or one or more of our affiliates that are unrelated to the transactions contemplated by the Purchase Agreement and the offering of shares for resale by B. Riley Principal Capital II to which this prospectus relates, for which investment banking and other financial services they have received and may continue to receive customary fees, commissions and other compensation from us, aside from any discounts, fees and other compensation that B. Riley Principal Capital II has received and may receive in connection with the transactions contemplated by the Purchase Agreement, (i) the 3.0% fixed discount to current market prices of our Class A Common Stock reflected in the purchase prices payable by B. Riley Principal Capital II for our Class A Common Stock that we may require it to purchase from us from time to time under the Purchase Agreement, and (ii) our reimbursement of up to an aggregate of $135,000 of B. Riley Principal Capital II’s legal fees ($75,000 upon execution of the Purchase Agreement and $5,000 per fiscal quarter for the maximum three year term of the Purchase Agreement) in connection with the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement.

LEGAL MATTERS

Greenberg Traurig, P.A. has passed upon the validity of the Class A Common Stock offered by this prospectus and certain other legal matters related to this prospectus.

EXPERTS

The financial statements of Mobix Labs Operations, Inc. (formerly known as Mobix Labs, Inc.) as of September 30, 2023 and September 30, 2022 and for the years then ended included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to Mobix Labs Operations, Inc.’s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

The financial statements of EMI Solutions as of June 30, 2023 and June 30, 2022 and for the years then ended included in this prospectus have been so included in reliance on the report of Macias Gini & O’Connell LLP, an independent public accounting firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Class A Common Stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further information with respect to the Company, the Class A Common Stock, reference is made to the registration statement and the exhibits and any schedules filed therewith.

Statements contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement being qualified in all respects by such reference.

The SEC maintains a website at www.sec.gov, from which interested persons can electronically access the registration statement, including the exhibits and any schedules thereto and which contains the periodic reports, proxy and information statements and other information that we file electronically with the SEC.

We are subject to the information reporting requirements of the Exchange Act and we are required to file reports, proxy statements and other information with the SEC. These reports, proxy statements, and other information are available for inspection and copying at the SEC’s website referred to above. We also maintain a website at https://www.investors.mobixlabs.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

INDEX TO FINANCIAL STATEMENTS